<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis - Lands, LC - 2019 | Cochrane Library</title> <meta content="Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis - Lands, LC - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001505.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis - Lands, LC - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001505.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001505.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis" name="citation_title"/> <meta content="Larry C Lands" name="citation_author"/> <meta content="Montreal Children's Hospital" name="citation_author_institution"/> <meta content="larry.lands@muhc.mcgill.ca" name="citation_author_email"/> <meta content="Sanja Stanojevic" name="citation_author"/> <meta content="The Hospital for Sick Children" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001505.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001505.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001505.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001505.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti‐Inflammatory Agents, Non‐Steroidal [administration &amp; dosage, *therapeutic use]; Cystic Fibrosis [*drug therapy]; Ibuprofen [administration &amp; dosage, therapeutic use]; Piroxicam [administration &amp; dosage, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001505.pub5&amp;doi=10.1002/14651858.CD001505.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001505\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001505\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","pl","fr","zh_HANS","ms","ru","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001505.pub5",title:"Oral non\\u2010steroidal anti\\u2010inflammatory drug therapy for lung disease in cystic fibrosis",firstPublishedDate:"Sep 9, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001505.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001505.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001505.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001505.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001505.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001505.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001505.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001505.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001505.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001505.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4786 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001505.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/appendices#CD001505-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/table_n/CD001505StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/table_n/CD001505StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information#CD001505-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Larry C Lands</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information#CD001505-cr-0003">Sanja Stanojevic</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information/en#CD001505-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001505.pub5">https://doi.org/10.1002/14651858.CD001505.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001505-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001505-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001505-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001505-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001505-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001505-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001505-abs-0001" lang="en"> <section id="CD001505-sec-0001"> <h3 class="title" id="CD001505-sec-0001">Background</h3> <p>Progressive lung damage causes most deaths in cystic fibrosis. Non‐steroidal anti‐inflammatory drugs (such as ibuprofen) may prevent progressive pulmonary deterioration and morbidity in cystic fibrosis. This is an update of a previously published review. </p> </section> <section id="CD001505-sec-0002"> <h3 class="title" id="CD001505-sec-0002">Objectives</h3> <p>To assess the effectiveness of treatment with oral non‐steroidal anti‐inflammatory drugs in cystic fibrosis. </p> </section> <section id="CD001505-sec-0003"> <h3 class="title" id="CD001505-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, hand searches of relevant journals and abstract books of conference proceedings. We contacted manufacturers of non‐steroidal anti‐inflammatory drugs and searched online trials registries. </p> <p>Latest search of the Group's Trials Register: 21 November 2018.</p> </section> <section id="CD001505-sec-0004"> <h3 class="title" id="CD001505-sec-0004">Selection criteria</h3> <p>Randomized controlled trials comparing oral non‐steroidal anti‐inflammatory drugs, at any dose for at least two months, to placebo in people with cystic fibrosis. </p> </section> <section id="CD001505-sec-0005"> <h3 class="title" id="CD001505-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trials for inclusion the review and their potential risk of bias. Two authors independently rated the quality of the evidence for each outcome using the GRADE guidelines. </p> </section> <section id="CD001505-sec-0006"> <h3 class="title" id="CD001505-sec-0006">Main results</h3> <p>The searches identified 17 trials; four are included (287 participants aged five to 39 years; maximum follow‐up of four years) and one is currently awaiting classification pending publication of the full trial report and two are ongoing. Three trials compared ibuprofen to placebo (two from the same center with some of the same participants); one trial assessed piroxicam versus placebo. </p> <p>The three ibuprofen trials were deemed to have good or adequate methodological quality, but used various outcomes and summary measures. Reviewers considered measures of lung function, nutritional status, radiological assessment of pulmonary involvement, intravenous antibiotic usage, hospital admissions, survival and adverse effects. Combined data from the two largest ibuprofen trials showed a lower annual rate of decline for lung function, % predicted forced expiratory volume in one second (FEV<sub>1</sub>), mean difference (MD) 1.32 (95% confidence interval (CI) 0.21 to 2.42) (moderate‐quality evidence); forced vital capacity (FVC), MD 1.27 (95% CI 0.26 to 2.28) (moderate‐quality evidence); forced expiratory flow (FEF<sub>25%‐75%</sub>), MD 1.80 (95% CI 0.15 to 3.45). The post hoc analysis of data from two trials split by age showed a slower rate of annual decline of FEV<sub>1</sub> % predicted and FVC in the ibuprofen group in younger children, MD 1.41% (95% CI 0.03 to 2.80) (moderate‐quality evidence) and MD 1.32% (95% CI 0.04 to 2.60) (moderate‐quality evidence) respectively. Data from four trials demonstrated the proportion of participants with at least one hospitalization may be slightly lower in the ibuprofen group compared to placebo, Peto odds ratio 0.61 (95% CI 0.37 to 1.01) (moderate‐quality evidence). In one trial, long‐term use of high‐dose ibuprofen was associated with reduced intravenous antibiotic usage, improved nutritional and radiological pulmonary status. No major adverse effects were reported, but the power of the trials to identify clinically important differences in the incidence of adverse effects was low. </p> <p>We did not have any concerns with regards to risk of bias for the trial comparing piroxicam to placebo. However, the trial did not report many data in a form that we could analyze in this review. No data were available for the review's primary outcome of lung function; available data for hospital admissions showed no difference between the groups. No analyzable data were available for any other review outcome. </p> </section> <section id="CD001505-sec-0007"> <h3 class="title" id="CD001505-sec-0007">Authors' conclusions</h3> <p>High‐dose ibuprofen can slow the progression of lung disease in people with cystic fibrosis, especially in children, which suggests that strategies to modulate lung inflammation can be beneficial for people with cystic fibrosis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001505-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001505-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001505-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001505-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001505-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD001505-abs-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001505-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001505-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001505-abs-0013">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001505-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001505-abs-0005" lang="en"> <h3>Treatment with oral drugs other than steroids to reduce lung inflammation and deterioration in lung function in people with cystic fibrosis </h3> <p><b>Review question</b> </p> <p>We reviewed evidence to see if drugs that were not steroids could reduce inflammation in the lungs and stop lung function getting worse in people with cystic fibrosis. </p> <p><b>Background</b> </p> <p>Inflammation in the lungs increases the damage done to them and is the most common reason for early death in people with cystic fibrosis. In high doses, non‐steroidal anti‐inflammatory drugs, particularly ibuprofen, may work against inflammation, but in low doses there is some evidence that they may cause the inflammation. The use of high doses has also raised concerns about the potential for unwanted effects, which has limited the use of these drugs in cystic fibrosis. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 21 November 2018.</p> <p><b>Study characteristics</b> </p> <p>We looked for trials comparing oral non‐steroidal anti‐inflammatory drugs to a a placebo (a tablet that contained no active medicine). We looked for any dose level. but the trial had to run for at least two months in people with cystic fibrosis. We found 17 trials and included four of these with a total of 287 people aged five to 39 years; one further trial has not yet been published in full and two are still ongoing; we will assess these when we have more information. Three of the four included trials compared ibuprofen to a placebo; two of these trials were run in the same center and used some of the same people. One trial compared a drug called piroxicam to placebo. The longest trial lasted four years. </p> <p>We aimed to report on lung function, nutritional status, lung x‐rays, how often intravenous antibiotics were needed, details about hospital admissions, survival and side effects. </p> <p><b>Key results</b> </p> <p>We combined results from the two largest ibuprofen trials and showed that those taking ibuprofen had a lower annual rate of decline in lung function which was consistent across three lung function measurements. We then looked at these results split by age (even though we did not originally plan to do this) and found that two of the measurements showed a slower rate of annual decline in lung function in younger children. Results from four trials showed that fewer participants in the ibuprofen group were admitted to hospital at least once compared to placebo, although it was not clear if the difference was just chance or not. In one trial, people taking a long‐term high dose of ibuprofen were less likely to need intravenous antibiotics, had better nutritional status and healthier lungs as seen by X‐ray. No major side effects were reported in the trials, but they had not been designed to show differences in the rates of side effects. </p> <p>To summarize, we found evidence showing that a high dose of a non‐steroidal anti‐inflammatory drug, most notably ibuprofen, may slow the progression of lung damage in people with cystic fibrosis, especially in younger people. The long‐term safety results are limited but we feel that there is enough evidence to suggest that non‐steroidal anti‐inflammatory drugs be temporarily stopped when people with cystic fibrosis are receiving intravenous aminoglycosides or other drugs that may badly damage the kidneys. </p> <p>The trial of the drug piroxicam did not report many results in a form that we could analyse in the review. We did not have any results for our main outcome of lung function. The only results we had reported no difference between the piroxicam group and the placebo group for the number of hospital admissions. </p> <p><b>Quality of the evidence</b> </p> <p>We judged the evidence to be of moderate quality overall. We thought the three ibuprofen trials had a good or adequate level of methodological quality with little risk of bias to the results, but used a range of different outcomes and summary measures. We did not have any concerns with regards to risks of bias for the trial comparing piroxicam to placebo. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001505-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001505-sec-0111"></div> <h3 class="title" id="CD001505-sec-0112">Implications for practice</h3> <section id="CD001505-sec-0112"> <p>The results of this review suggest that high‐dose ibuprofen probably slows the progression of lung disease in children with cystic fibrosis (CF). There may also be a beneficial effect on the number of days spent in hospital and ibuprofen appears to be relatively well‐tolerated. However, the long‐term effects of prolonged use of high doses of oral non‐steroidal anti‐inflammatory drugs (NSAIDs) have yet to be determined. Furthermore, gastrointestinal protection is required as are regular pharmacokinetic trials and safety profiles. </p> <p>The need to repeat pharmacokinetic analyses in people taking ibuprofen is important to note. The current programs using ibuprofen suggest repeating these assays at least every two years, but more frequent follow‐up is necessary if there is a weight change of more than 25%. It is suggested that hematologic, renal, and hepatic status are monitored annually. </p> <p>Given the findings on adverse events from non‐randomised studies as outlined above and the evidence on adverse effects from this review, the use of NSAIDs should be temporarily discontinued during intravenous administration of aminoglycosides and possibly colymycin (colistin) (<a href="./references#CD001505-bbs2-0018" title="BertenshawC , WatsonA , LewisS , SmythA . A survey of acute renal failure in cystic fibrosis patients in the United Kingdom. http://thorax.bmj.com/ (accessed 30 January 2007). ">Bertenshaw 2007</a>). Furthermore, individuals with esophagitis or peptic ulcer disease should not use high‐dose ibuprofen. Individuals with recurrent significant hemoptysis should also not be placed on this treatment. </p> </section> <h3 class="title" id="CD001505-sec-0113">Implications for research</h3> <section id="CD001505-sec-0113"> <p>The clinical variability of CF suggests that it may be helpful for future updates of this systematic review to be based on individual patient data rather than on the published trial reports, as this will allow appropriate meta‐analysis of within‐participant changes from baseline. All trials should be designed to be of adequate power to reliably identify important adverse events such as, for example, major gastrointestinal haemorrhage. Multicenter trials will add to the validity of findings by enhancing their generalisability. </p> <p>While this review suggests that NSAID therapies probably slow down the rate of lung function decline in people with CF, further work is required to understand the mechanism of action so that therapies with enhanced safety profiles can be developed. Trials examining the effectiveness and safety of long‐term use of NSAIDs and other anti‐inflammatory therapies are required in young symptomatic children as well as very young pre‐symptomatic children. </p> <p>Monitoring the effects of therapeutic treatment relies on appropriate detection of important clinical changes in lung function. Since a biological marker for identifying lung function changes has yet to be identified, follow‐up studies require recruitment of a sufficiently large sample, followed repeatedly over a period deemed adequate to detect important clinical changes which are a direct result of the therapeutic intervention. </p> <p>Future trials need to address the age at which therapy is most effective. While pulmonary function and nutritional status are the primary outcomes of interest, evidence for a reduction in concomitant therapy, specifically intravenous antibiotic use, as well as in hospital admissions for respiratory exacerbations, should be sought. Evidence from this review suggests that there may be important reductions in days spent in hospital for all causes, but these findings require confirmation in other studies, which ideally should identify hospital admissions for respiratory exacerbations separately. These secondary outcome measures may have important implications for cost‐effectiveness of treatment as well as quality of life. Although there are methodological problems in measuring quality of life for very young children, it is feasible to measure quality of life in older children and in their parents or carers. Future trials should begin to assess these outcomes as, given the current median survival for CF, quality of life assumes greater relevance. </p> <p>Finally, the effectiveness of NSAIDs may need to be re‐investigated in the era of CF modulator therapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001505-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001505-sec-0036"></div> <div class="table" id="CD001505-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: NSAIDs </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>All participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.15%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the NSAIDs group was <b>1.32% higher</b> (0.21 higher to 2.42 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>Subgroup: under 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.32%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted for under 13 year olds in the NSAIDs group was <b>1.41% higher</b> (0.03 higher to 2.80 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>Subgroup: over 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.18%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted for over 13 year olds in the NSAIDs group was <b>0.75% higher</b> (1.02 lower to 2.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>All participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.31%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the NSAIDs group was <b>1.27% higher</b> (0.26 higher to 2.28 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>Subgroup: Under 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.65%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted for under 13 year olds in the NSAIDs group was <b>1.32% higher</b> (0.04 higher to 2.60 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>Subgroup: Over 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.03%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted for over 13 year olds in the NSAIDs group was 0.78<b>% higher</b> (0.71 lower to 2.27 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with at least 1 hospital admission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>440 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>268 per 1000</p> <p>(163 to 444)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.61 (0.37 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>FVC:</b> forced vital capacity; <b>NSAIDs:</b> non‐steroidal anti‐inflammatory drugs; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to high risk of bias due to selective reporting.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001505-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001505-sec-0037"></div> <section id="CD001505-sec-0038"> <h3 class="title" id="CD001505-sec-0038">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common recessively inherited genetic condition affecting people of Northern European descent (<a href="./references#CD001505-bbs2-0020" title="FarrellP , FérecC , MacekM , FrischerT , RennerS , RissK , et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics2018;26(12):1832‐9. [DOI: 10.1038/s41431‐018‐0234‐z] ">Farrell 2018</a>). It is estimated that, among Northern Europeans, one person out of 25 is a carrier of a CF gene and that one child out of every 2500 born is affected, with other populations affected to a lesser extent (<a href="./references#CD001505-bbs2-0031" title="RosensteinBJ , CuttingGR . The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics1998;132(4):589‐95. ">Rosenstein 1998</a>). The most important clinical manifestation in CF is progressive pulmonary deterioration, which is associated with recurrent lower respiratory tract illnesses, respiratory failure and death. As morbidity and mortality among those with CF is largely a consequence of these respiratory complications, the pathogenesis of respiratory disease in CF and the prevention of pulmonary deterioration are important therapeutic goals. </p> <p>The role of airway inflammation in mediating lung injury among those with CF has received increasing attention (<a href="./references#CD001505-bbs2-0024" title="KonstanMW , BergerM . Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatric Pulmonology1997;24(2):137‐42. ">Konstan 1997</a>). Persistent infection of the airways with <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus aureus</i> or <i>Haemophilus influenzae</i> is thought to contribute to a hyperactive inflammatory response, with cytokines, proteases, oxygen radicals and elastase being released profusely once infection is established (<a href="./references#CD001505-bbs2-0019" title="ChmielJF , BergerM , KonstanMW . The role of inflammation in the pathophysiology of CF lung disease. Clinical Reviews in Allergy &amp; Immunology2002;23(1):5‐27. ">Chmiel 2002</a>; <a href="./references#CD001505-bbs2-0021" title="GibsonRL , BurnsJL , RamseyBW . Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal Respiratory and Critical Care Medicine2003;168(8):918‐51. ">Gibson 2003</a>). These mediators of inflammation are likely to make an important contribution to airway damage. In addition, persistent stimulation of the immune system leads to high serum and tissue IgG levels, accompanied by extensive neutrophil infiltration. This combination of cellular and biochemical events form part of a cascade of inflammation which is associated with progressive and irreversible airway damage in CF. </p> </section> <section id="CD001505-sec-0039"> <h3 class="title" id="CD001505-sec-0039">Description of the intervention</h3> <p>Non‐steroidal anti‐inflammatory drugs (NSAIDs) are agents that affect the cyclo‐oxygenase pathway, resulting in inhibition of prostaglandin synthesis and, at high doses, ibuprofen also affects the lipoxygenase pathway. However, uncertainty remains regarding the exact mode of action of ibuprofen and it has been suggested that, at low doses, ibuprofen may be pro‐inflammatory (<a href="./references#CD001505-bbs2-0026" title="KonstanMW , KrenickyJE , FinneyMR , KirchnerHL , HilliardKA , HilliardJB , et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. Journal of Pharmacology and Experimental Therapeutics2003;306(3):1086‐91. ">Konstan 2003</a>). Mean peak plasma concentrations of greater than 50 micrograms per milliliter (μg/mL) have been associated with maximal anti‐inflammatory effect. A potentially narrow therapeutic window for ibuprofen may exist, as experimental work in animals and humans suggests that low plasma concentrations may be associated with a paradoxical increase in inflammation. In view of this, the importance of maintaining high plasma levels in the therapeutic range based on pharmacokinetic trials and careful pharmacological monitoring to devise optimal individual dosing schedules has been stressed. </p> <p>Difficulties in access to pharmacological assays with which to optimize individual dosing schedules, combined with concerns regarding potential adverse effects of NSAIDs, may be important considerations. Recent debates in literature about safety of low‐dose NSAIDs and cardiovascular disease further highlights the need for careful monitoring of pharmacokinetic levels. The likelihood of adverse events among people with CF may be increased in the presence of impaired liver or renal function, and these in turn may influence plasma levels of potentially toxic co‐therapy such as, for example, with aminoglycosides. This emphasizes the importance of assessing these consequences adequately within the context of randomized trials. </p> </section> <section id="CD001505-sec-0040"> <h3 class="title" id="CD001505-sec-0040">How the intervention might work</h3> <p>As pulmonary damage in CF may occur as a consequence of inflammation, it has been hypothesized that prolonged use of NSAIDs may prevent progressive pulmonary deterioration and respiratory morbidity. </p> <p>Previous trials have provided circumstantial evidence in support of this hypothesis. In the Wheeler trial, the authors observed that, among young children with CF, respiratory status was better in those with very low serum IgG levels compared to age‐matched CF children with normal or elevated serum IgG (<a href="./references#CD001505-bbs2-0033" title="WheelerWB , WilliamsRN , MatthewsWJ , ColtenHR . Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5‐year longitudinal study. Journal of Pediatrics1984;104(5):685‐99. ">Wheeler 1984</a>). Konstan infected a group of rats with <i>P aeruginosa</i> and then treated them with either ibuprofen or placebo for 14 days (<a href="./references#CD001505-bbs2-0023" title="KonstanMW , VargoKM , DavisPB . Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. American Review of Respiratory and Critical Care Medicine1990;141(1):186‐92. ">Konstan 1990</a>). The active treatment group had 30% less lung inflammation than the placebo‐treated group. Although the rat model for pulmonary infection with <i>P aeruginosa</i> is different from human CF in many ways, the above results offer further support for the hypotheses that: </p> <p> <ol id="CD001505-list-0001"> <li> <p>there is an immunological or inflammatory component to lung function decline in CF; and </p> </li> <li> <p>treatment with NSAIDs may delay progression of Pseudomonas‐related lung disease in people with CF. </p> </li> </ol> </p> </section> <section id="CD001505-sec-0041"> <h3 class="title" id="CD001505-sec-0041">Why it is important to do this review</h3> <p>This systematic review aims to establish whether administering oral high‐dose NSAIDs to people with CF alters the pattern of change in specific clinical markers of CF‐related disease progression. Specifically, it aims to explore the extent to which existing evidence supports a beneficial effect of NSAIDs on lung function and respiratory morbidity in people with CF. The potential negative effects of such treatment, especially when given over prolonged periods, will also be considered. Recognized adverse effects of NSAIDs include: minor and major haemorrhage (life‐threatening gastrointestinal bleed, haemorrhagic stroke); gastrointestinal upset (dyspepsia, nausea); diarrhoea; allergic reactions (rash, fever); tinnitus; bronchospasm; and fluid retention. </p> <p>The original review summarizing three trials found preliminary evidence to suggest that non‐steroidal anti‐inflammatory drugs may prevent pulmonary deterioration in people with mild lung disease due to CF, but that their routine use could not be recommended (<a href="./references#CD001505-bbs2-0034" title="DezateuxC , CrightonA . Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis. Cochrane Database of Systematic Reviews1999, Issue 2. [DOI: 10.1002/14651858.CD001505] ">Dezateux 1999</a>). This is an updated version of previously published reviews (<a href="./references#CD001505-bbs2-0034" title="DezateuxC , CrightonA . Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis. Cochrane Database of Systematic Reviews1999, Issue 2. [DOI: 10.1002/14651858.CD001505] ">Dezateux 1999</a>; <a href="./references#CD001505-bbs2-0035" title="LandsLC , DezateuxC , CrightonA . Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD001505] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0036" title="LandsLC , StanojevicS . Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD001505.pub2] ">Lands 2009</a>; <a href="./references#CD001505-bbs2-0037" title="LandsLC , StanojevicS . Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD001505.pub3] ">Lands 2013</a>; <a href="./references#CD001505-bbs2-0038" title="LandsLC , StanojevicS . Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001505.pub4] ">Lands 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001505-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001505-sec-0042"></div> <p>The objective of this review is to determine the effectiveness of treatment with oral NSAIDs in preventing pulmonary deterioration and maintaining an optimal level of pulmonary function among those with CF. Specifically, we wished to examine the hypotheses that treatment with oral NSAIDs for a period of two months or more: </p> <p> <ol id="CD001505-list-0002"> <li> <p>improves or prevents deterioration in objective measures of lung function;</p> </li> <li> <p>reduces the need for intravenous antibiotic therapy for respiratory exacerbations;</p> </li> <li> <p>reduces the need for hospital admissions for respiratory exacerbations;</p> </li> <li> <p>reduces the number of days spent in hospital for respiratory exacerbations;</p> </li> <li> <p>improves quality of life;</p> </li> <li> <p>improves survival;</p> </li> <li> <p>is associated with adverse effects (including major hemorrhage such as a life‐threatening gastrointestinal bleed or hemorrhagic stroke, gastrointestinal (GI) upset including dyspepsia or nausea, diarrhoea, allergic reactions (rash, fever), tinnitus, bronchospasm or fluid retention). </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001505-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001505-sec-0043"></div> <section id="CD001505-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001505-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs), published and unpublished.</p> </section> <section id="CD001505-sec-0046"> <h4 class="title">Types of participants</h4> <p>Children and adults, of any age, with defined CF, diagnosed clinically and by quantitative sweat chloride testing or genetic testing or both. People with CF at all stages of lung disease were included. </p> </section> <section id="CD001505-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Non‐steroidal anti‐inflammatory drugs (NSAIDs) administered orally at any dose for a period of at least two months compared to placebo or existing conventional therapy. </p> </section> <section id="CD001505-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD001505-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001505-list-0003"> <li> <p>Objective measures of lung function (measured as absolute change in % predicted from baseline compared to control and post‐treatment change in % predicted compared to control): </p> <ol id="CD001505-list-0004"> <li> <p>forced expiratory volume in one second (FEV<sub>1</sub>) </p> </li> <li> <p>forced vital capacity (FVC)</p> </li> <li> <p>forced expiratory flow 25%‐75% (FEF<sub>25%‐75%</sub>) </p> </li> </ol> </li> </ol> </p> </section> <section id="CD001505-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001505-list-0005"> <li> <p>Number of days of intravenous antibiotic therapy for respiratory exacerbations</p> </li> <li> <p>Number of hospital admissions for respiratory exacerbations</p> </li> <li> <p>Number of hospital days for respiratory exacerbations</p> </li> <li> <p>Quality of life (QoL) measures</p> </li> <li> <p>Proportion surviving at six months and one year</p> </li> <li> <p>Nutritional status as noted by weight gain, body mass index (BMI), z score or other indices of nutritional state </p> </li> <li> <p>Chest x‐ray scores</p> </li> <li> <p>Adverse effects (such as minor haemorrhage, major hemorrhage (life‐threatening GI bleed, hemorrhagic stroke), GI upset (dyspepsia, nausea), diarrhoea, allergic reactions (rash, fever), tinnitus, bronchospasm, fluid retention) </p> </li> <li> <p>Dropout rates</p> </li> </ol> </p> </section> </section> </section> <section id="CD001505-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>Trials are eligible for inclusion irrespective of language or publication status.</p> <section id="CD001505-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Cystic Fibrosis Trials Register using the terms: anti‐inflammatory AND (non‐steroidal OR other) AND (oral OR not stated). </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the<i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of EMBASE to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 21 November 2018. </p> <p>We also searched clinicaltrials.gov and the WHO ICTRP (see <a href="./appendices#CD001505-sec-0117">Appendix 1</a>); date of latest search: 07 February 2019. </p> </section> <section id="CD001505-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of identified publications for additional references. We contacted the pharmaceutical companies which manufacture NSAIDs by letter with requests for information on any published or unpublished trials using NSAIDs in CF. </p> </section> </section> <section id="CD001505-sec-0054"> <h3 class="title" id="CD001505-sec-0054">Data collection and analysis</h3> <section id="CD001505-sec-0055"> <h4 class="title">Selection of studies</h4> <p>At the time of the initial review two authors (CD and AC) independently applied inclusion criteria to all potential reports. Subsequently, from 2007 onwards, two different authors (SS and LL) assessed the inclusion criteria of all identified trials. The authors resolved any disagreements by discussion. </p> </section> <section id="CD001505-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>The authors independently extracted data using a standard data extraction form.</p> <p>In order to directly compare pulmonary function outcomes in the pediatric population as defined in the Konstan trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>), authors re‐analyzed data from the Trans‐Canadian trial by stratifying the data at 13 years of age (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> <section id="CD001505-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In order to establish a risk of bias for each included trial, the authors assessed the methodological quality of the included trials. The authors recorded details of the following: concealment and generation of the randomization sequence; whether the trial was blinded; whether intention‐to‐treat analyses were possible from the available data; and whether the report documented the number of participants lost to follow‐up or subsequently excluded from the trial. </p> <p>If the review authors judged both generation of sequence and concealment of allocation to be adequate, this corresponded to a low risk of bias; if the review authors judged these to be inadequate, this corresponded to a high risk of bias and if they judged these criteria to be unclear, the risk of bias too was judged to be unclear. </p> <p>For blinding, the risk of bias decreased if more people (participants, clinicians or outcome assessors) were blinded to the intervention. The risk of bias was unclear if the trials did not describe the degree of blinding used. </p> <p>Regarding incomplete outcome data, there was a risk of bias if a number of participants withdrew or were lost to follow‐up with no good reason supplied or if the reasons differed across groups. The risk of bias was low if the amount of missing data was approximately equal and balanced across groups. If the trial authors did not clearly report the numbers randomized into each intervention group, the review authors judged the risk of bias from missing data to be unclear. </p> </section> <section id="CD001505-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>The review authors proposed a pooled estimate of the treatment effect for each outcome measure across trials, specifically the odds of an outcome among treatment‐allocated participants to the corresponding odds among controls. We considered improvement in any of those outcomes that demonstrated efficacy of treatment to be beneficial. </p> <p>For continuous outcomes (e.g. lung function, QoL measures, weight, etc.), we calculated the mean difference (MD) and the 95% confidence intervals (CI) and for dichotomous outcomes (e.g. number surviving at six months and one year, adverse effects), the Peto odds ratio (OR) and the 95% CIs. </p> </section> <section id="CD001505-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The review authors do not feel that cross‐over trials are appropriate for assessing the treatment effects of NSAIDs in CF, as CF is a progressive disease and requires a longer follow‐up period. In the future, we will consider whether to include any identified cross‐over trials on an individual basis. </p> </section> <section id="CD001505-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>In order to allow an intention‐to‐treat analysis, the authors sought data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance or subsequent exclusion from treatment or follow‐up. </p> <p>The review authors contacted the primary authors of the trials for any information required for the analysis which did not appear in the published trial reports. They were unable to obtain original data from Dr M. Konstan for the 13‐ to 18‐year old participants from the 1995 study to make the Konstan and Lands studies less heterogeneous (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> <section id="CD001505-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity between trial results was examined using a Chi² test and the I² statistic (<a href="./references#CD001505-bbs2-0022" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The I² statistic describes the percentage of total variation across trials that is due to heterogeneity rather than by chance and its values lie between 0% and 100%. The review authors used a simplified categorization of heterogeneity (low (I² value of 25%), moderate (I² value of 50%), and high (I² value of 75%) (<a href="./references#CD001505-bbs2-0022" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>)). </p> </section> <section id="CD001505-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>The review authors assessed reporting bias to ensure trial investigators reported all outcomes listed in the methods in the results. Where possible, the review authors viewed the original trial protocol. If they had been able to identify and include a sufficient number of trials, they would have used a funnel plot to quantify any publication bias. </p> </section> <section id="CD001505-sec-0063"> <h4 class="title">Data synthesis</h4> <p>The review authors have analyzed available data using a fixed‐effect model. If in future they are able to include further trials and identify at least moderate heterogeneity as defined above, they plan to analyze the data using a random‐effects model. </p> </section> <section id="CD001505-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The review authors used available data to analyze the effect of NSAIDs in a subgroup of young participants (under 13 years of age) with mild lung disease and a separate subgroup of older participants (over 13 years of age) with moderate or severe lung disease. The age‐stratified data were not published in the Canadian Trial and were obtained directly from the authors. </p> </section> <section id="CD001505-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>If in future sufficient data are available, the review authors plan to conduct a sensitivity analysis to test the robustness of their results excluding outlying centers or centers identified with high risk of bias or both. </p> <section id="CD001505-sec-0066"> <h5 class="title">Summary of findings tables</h5> <p>We have now included a summary of findings table for the comparison of oral NSAID therapy and placebo. We have selected the following outcomes, which we consider to be the most important, to include in the table. </p> <p> <ol id="CD001505-list-0006"> <li> <p>Annual rate of change in % predicted FEV<sub>1</sub> (total cohort) </p> </li> <li> <p>Annual rate of change in % predicted FEV<sub>1</sub> (under 13 years of age at randomization) </p> </li> <li> <p>Annual rate of change in % predicted FEV<sub>1</sub> (over 13 years of age at randomization) </p> </li> <li> <p>Annual rate of change in % predicted FVC (total cohort)</p> </li> <li> <p>Annual rate of change in % predicted FVC (under 13 years of age at randomization)</p> </li> <li> <p>Annual rate of change in % predicted FVC (over 13 years of age at randomization)</p> </li> <li> <p>Proportion with at least one hospital admission</p> </li> </ol> </p> <p>We used the GRADE approach to assess the quality of the evidence for each outcome based on the risk of bias within the trials, relevance to our population of interest (indirectness), unexplained heterogeneity or inconsistency, imprecision of the results or high risk of publication bias. We downgraded the evidence once if the risk was serious and twice if the risk was deemed to be very serious. </p> <p>The effects of ibuprofen may be more beneficial in individuals with mild disease in whom fixed structural damage has not yet occurred, therefore, similar to one of the previous trials we stratified the analysis by age (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001505-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001505-sec-0067"></div> <section id="CD001505-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD001505-sec-0069"> <h4 class="title">Results of the search</h4> <p>The searches to date have identified a total of 36 references to 17 trials. There are currently four trials (eight references) included (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>), 10 trials (23 references) excluded (<a href="./references#CD001505-bbs2-0005" title="ChmielJF , KonstanMW , AccursoFJ , LympJ , Mayer‐HamblettN , VanDevanterDR , et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis2015;14(6):720‐6. [CFGD Register: PI218b] ChmielJF , KonstanMW , LympJ , Mayer‐HamblettN , HilliardKA , AccursoFJ , et al. Assessment of induced sputum as a tool to evaluate anti‐inflammatory agents in CF. Pediatric Pulmonology2007;42 Suppl 30:228. [CFGD Register: PI218a] ">Chmiel 2007</a>; <a href="./references#CD001505-bbs2-0006" title="GonzalezV , SieglerN , CrandallR , MckieKT , ForseenC , Rodriguez‐MiguelezP , et al. Acute sildenafil treatment improves exercise capacity in patients with cystic fibrosis. FASEB Journal. Experimental Biology Abstracts2018;32(Supplement 1):no pagination. [Abstract No.: 853.5; CFGD Register: IB124] ">Gonzalez 2018</a>; <a href="./references#CD001505-bbs2-0007" title="HuntK , StClairC , Curran‐EverettD , SolomonGM , SaavedraMT , NickJA , et al. CFTR effects of oral sildenafil in combination with lumacaftor/ivacaftor in adults with CF. Pediatric Pulmonology2017;52 Suppl 47:322. [CFGD Register: IB117] ">Hunt 2017</a>; <a href="./references#CD001505-bbs2-0008" title="KovalevaLF , GuembitskaiaTE , GorbenkoIA , AleshinYuN . Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:155. [CFGD Register: IB91] ">Kovaleva 2000</a>; <a href="./references#CD001505-bbs2-0009" title="NoritakeD , HenJ , DolanTF . Effects of aspirin on pulmonary function in patients with cystic fibrosis. Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:144. [CFGD Register: IB4b] NoritakeDT , HenJ , LeoL , DolanTF . The influence of aspirin on lung function in cystic fibrosis. Connecticut Medicine1982;46:574‐6. [CFGD Register: IB4a] ">Noritake 1982</a>; <a href="./references#CD001505-bbs2-0010" title="PukhalskyAL , ShmarinaGV , KapranovNI , KakorovtsevaSN , PukhalskayaD , KashirskajaNJ . Anti‐inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediator of Inflammation2004;13(2):111‐7. [CENTRAL: 997725; CFGD Register: IB44c; CRS: 5500125000000705; PUBMED: 15203552] PukhalskyAL , ShmarinaGV , KaproanovNI , KashirskajaNJ , KokarovtsevaSN , ShabalovaLA . Increase of the sputumneutrophil elastase activity in a paradoxical effect of the successful lung disease treatment in cystic fibrosis. Pediatric Pulmonology2001;32 (Suppl 22):274. [CFGD Register: IB44b] ShmarinaGV , PukhalskyAL , KashirskajaNJ . Anti‐inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase‐2 inhibitor) and clarithromycin (14‐membrered ring macrolide antibiotic). European Respiratory Journal. 2004; Vol. Suppl 48:P3758. [CFGD Register: IB44a] ">Shmarina 2004</a>; <a href="./references#CD001505-bbs2-0011" title="AhujaS , SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , et al. CTX‐ 4430 in a phase 1 clinical trial in cystic fibrosis patients. Pediatric Pulmonology2015;50 Suppl 41:299. [Abstract no. : 287; CENTRAL: 1092202; CFGD Register: IB107d; CRS: 5500135000001391] SpringmanE , BhattL , GrosswaldR , PhilpotE . Pharmacokinetic and pharmacodynamic profile of CTX ‐4430 in two phase 1 studies. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 127; CENTRAL: 1077210; CFGD Register: IB107c; CRS: 5500135000001299] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Inflammation Research2015;64(2 Suppl 1):S206‐7. [Abstract no.: B261; CENTRAL: 1107950; CFGD Register: IB107e; CRS: 5500050000000292; EMBASE: 71973697] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 126; CENTRAL: 1077211; CFGD Register: IB107b; CRS: 5500135000001300] SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Pediatric Pulmonology2014;49 Suppl 38:311. [Abstract no.: 267; CENTRAL: 1012389; CFGD Register: IB107a; CRS: 5500131000000163] ">Springman 2014</a>; <a href="./references#CD001505-bbs2-0012" title="Taylor‐CousarJL , HuntKC , ClairC , EverettDC , NickJA , SaavedraMT , AbmanSH . A randomised controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis. Journal of Cystic Fibrosis2018;17 Suppl 3:S26. [Abstract no.: WS14.5; CFGD Register: IB121a] Tayor‐CousarJL , HuntKC , St. ClairC , EverettD , FensterB , NickJA , et al. Sildenafil improves cardiac performance, exercise intolerance and quality of life in moderate to severe cf lung disease. Pediatric Pulmonology2018;53 Suppl 2:226‐7. [Abstract no.: 212; CFGD Register: IB121b] ">Taylor‐Cousar 2017</a>; <a href="./references#CD001505-bbs2-0013" title="VargasMH , Del‐Razo‐RodriguezR , Lopez‐GarciaA , Lezana‐FernandezJL , ChavezJ , FuruyaMEY , et al. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial. BMC Pulmonary Medicine2017;17(1):206. [CFGD Register: IB125a; DOI: 10.1186/s12890‐017‐0528‐x] ">Vargas 2017</a>; <a href="./references#CD001505-bbs2-0014" title="CallahanKA , Diener‐WestM , SchoeberleinC , BoyleMP , ZeitlinPL . Preliminary safety profile of digitoxin to treat CF. Pediatric Pulmonology2014;49(Suppl 38):293. [Abstract no.: 219; CFGD Register: IB109b] LeeS , WalkerD , ZeitlinP . Nasal microarray analysis in CF subjects taking digitoxin. Pediatric Pulmonology2015;50 Suppl 41:292. [Abstract no.: 267; CFGD Register: IB109c] ZeitlinP , Diener‐WestM , CallahanKA , PollardB , LechtzinN , BoyleMP . Phase II study of digitoxin for CF. Pediatric Pulmonology2015;50 Suppl 41:268. [Abstract no.: 207; CFGD Register: IB109d] ZeitlinPL . Phase II study of digitoxin to treat cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00782288 (first posted 31 October 2008). [CFGD Register: IB109a] ZeitlinPL , Diener‐WestM , CallahanKA , LeeS , TalbotCCJr , PollardB , et al. Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding. Annals of the American Thoracic Society2017;14(2):220‐9. [CFGD Register: IB109e; ] ">Zeitlin 2017</a>), two trials with one reference each are ongoing (<a href="./references#CD001505-bbs2-0016" title="NCT03265288 . Study of LAU‐7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD). clinicaltrials.gov/ct2/show/NCT03265288 (first posted 29 August 2017). ">APPLAUD 2017</a>; <a href="./references#CD001505-bbs2-0017" title="NCT03451045 . Trial to evaluate efficacy and safety of lenabasum in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03451045 (first posted 01 March 2018). ">NCT03451045</a>) and one trial with three references is listed as awaiting classification (<a href="./references#CD001505-bbs2-0015" title="ElbornJ , Taylor‐CousarJL , RoweSM , GrosswaldR , MershonJ , SpringmanE , et al. A phase 2 trial (EMPIRE CF) of a novel anti‐inflammatory molecule, acebilustat, in patients with cystic fibrosis. Pediatric Pulmonology2018;53 Suppl 2:227‐8. [Abstract no.: 214; CFGD Register: IB122c] ElbornJS , AhujaS , MershonJ , SpringmanE , RoweSM . Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF). Journal of Cystic Fibrosis2018;17(Suppl 3):S27. [CFGD Register: IB122a] ElbornJS , AhujaS , SpringmanE , MershonJ , GrosswaldR , RoweSM . EMPIRE‐CF: a phase II randomized placebo‐controlled trial of once‐daily, oral acebilustat in adult patients with cystic fibrosis ‐ Study design and patient demographics. Contemporary Clinical Trials2018;72:86‐94. [CFGD Register: IB122b] ">EMPIRE 2018</a>). </p> <p>The original 1999 review identified the ongoing Canadian trial which was later included in this review in 2007 (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> <section id="CD001505-sec-0070"> <h4 class="title">Included studies</h4> <p>The review currently includes four trials (eight references) (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> <section id="CD001505-sec-0071"> <h5 class="title">Trial design</h5> <p>All four trials were double‐blind placebo‐controlled RCTs (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Two were multicenter trials, one in the USA (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) and the second in Canada (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>), one trial was a single‐center trial in Argentina (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>) and it is not clear if the remaining trial was single or multicenter (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). The duration of the trials varied from two to four years in three trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>), but was not clear in the remaining trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> <section id="CD001505-sec-0072"> <h5 class="title">Participants</h5> <p>The participants included in the four eligible trials ranged from five to 39 years of age. In two separate trials from the same center, eligibility was defined according to an objective measure of lung function (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the first trial, participants with mild to moderate lung disease were included, defined as those in whom FEV<sub>1</sub> was more than 30% of that predicted for age, sex and height (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In addition, only those judged to be clinically stable, without a history of adverse effects with NSAIDs, and not taking 'interfering medication' were included. In the second trial, only those participants in whom FEV<sub>1</sub> was more than 60% predicted were included (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Additional criteria were employed in this trial, namely that participants had not received intravenous antibiotics in the preceding two months; inhaled sodium cromoglycate in the preceding six months; or inhaled or systemic corticosteroids in the preceding two years. Individuals were also excluded if they were known to: be hypersensitive to NSAIDs; have allergic bronchopulmonary aspergillosis; have a respiratory isolate of <i>Burkholderia cepacia</i>; or have hepatic, cardiovascular, renal, neurological, hematological or peptic ulcer disease. </p> <p>In the third trial by Sordelli, eligibility was defined by a combination of microbiological, anthropometric and clinical features; namely, previous sputum culture positive for <i>P aeruginosa</i>, a Schwachman score less than 50, body weight greater than 15 kg, an ability to swallow medication and an ability to comply with pulmonary function tests (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> <p>The Canadian multicenter trial recruited children with a sweat chloride diagnosis of CF and an FEV<sub>1</sub> greater than 60% predicted at time of entry into the trial (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Children were excluded if they had been hospitalized in the two months prior to entry, or if they had taken corticosteroids or NSAIDs for more than one month in the past year, had abnormal hepatic, renal, hematologic disorders or coagulopathy, documented evidence of peptic ulcer disease (endoscopy) or allergic bronchopulmonary aspergillosis, or a history of hypersensitivity reactions to NSAIDs. </p> </section> <section id="CD001505-sec-0073"> <h5 class="title">Interventions</h5> <p>Three of the trials examined ibuprofen compared with placebo (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>), while a fourth reported the use of piroxicam (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). In the first Konstan trial reporting ibuprofen, children were enrolled in a randomized double‐blind placebo‐controlled three‐month dose escalation trial (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). This trial examined the pharmacokinetics of ibuprofen, to identify the optimal dose and to evaluate adverse effects of ibuprofen treatment in children treated over a three‐month treatment period (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). This first trial contributed to the design of the second trial from this center, which examined the long‐term use of ibuprofen given over a four‐year period (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). The most recent trial from Canada is the biggest trial of NSAIDs in a CF population, following 142 children aged 6 to 18 years over a period of two years (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the trial of piroxicam, participants were assigned to piroxicam for a period of between 12 and 19 months (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> <p>In each trial the NSAID was compared with placebo. In the first Konstan trial, 13 children were randomized to receive ibuprofen and five to receive placebo, both of which were given for between one and three months (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). The dose of ibuprofen was 300 mg twice daily in the first month, increasing to 400 mg in the second month and 600 mg in the third month, if peak plasma concentrations of ibuprofen were less than 50 µg/mL (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the second Konstan trial, 42 participants were randomized to ibuprofen and 43 to placebo (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). All participants underwent a baseline pharmacokinetics trial employing 20 mg tablets at a dose of 20 to 30 mg/kg to a maximum of 1600 mg. The number of assigned pills was adjusted to provide a peak plasma concentration of 50 to 100 µg/mL. The participants took the prescribed dose twice daily and were followed for four years. This dose was revised if body weight increased by more than 25% during the trial and was reviewed in all participants during the third year to take account of increased body weight (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the double‐blind Canadian trial, participants were allocated treatment by a centralized pharmacy, using a predefined block randomization schedule (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Like Konstan's second ibuprofen trial, all participants underwent a baseline pharmacokinetics trial employing 200 mg tablets at a dose of 20 to 30 mg/kg to a maximum of 1600 mg. The number of assigned pills was adjusted to provide a peak plasma concentration of 50 to 100 μg/mL for each participant in the trial. The participants took the prescribed dose twice daily and were followed bi‐annually for two years (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the piroxicam trial, a single morning dose of between 5 to 20 mg, determined by participant's body weight, was given (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> <section id="CD001505-sec-0074"> <h5 class="title">Outcome measures</h5> <p>Of the outcomes specified in the prior hypotheses of the review FEV<sub>1</sub>, FVC and FEF<sub>25%‐75%</sub> were reported in all four trials comparing an NSAID to placebo. However, the specific summary measures employed and the interval between starting treatment and assessing lung function varied between the four trials. In the first Konstan trial, FEV<sub>1</sub> was summarized as group mean (standard deviation (SD)) of % predicted at entry to the trial and after an interval of two months (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the second Konstan trial, the primary outcome measure was the annual rate of change in % predicted FEV<sub>1</sub> over the four‐year period of treatment, with annual rate of change in % predicted FVC, FEF<sub>25%‐75%</sub> and body weight as secondary outcomes (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). The Canadian trial reported the difference in mean annual rate of decline in FEV<sub>1</sub> % predicted, FVC % predicted and FEF<sub>25%‐75%</sub> predicted (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Secondary outcomes included chest radiography, nutritional status (BMI, weight z score), overall hospitalization rates as well as specific hospitalization rates for respiratory and gastrointestinal admissions. In the piroxicam trial, FEV<sub>1</sub>, FVC and FEF<sub>25%‐75%</sub> were presented graphically as group means and standard errors of the absolute values, assessed at approximately four‐monthly intervals (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Participants were then categorized according to whether their respiratory function status was 'worse' or 'not worse' (the latter as determined by a more than 10% improvement in one or more of the respiratory function parameters). </p> <p>Chest X‐ray (Brasfield) scores were reported in three trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). In two trials these were summarized as the number showing improvement or deterioration (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>), rather than a specific score as in the piroxicam trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> <p>Change in weight was reported in two trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Konstan reported % ideal body weight and its change over four years (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Although weight gain was evaluated in the piroxicam trial, this was grouped into a clinical status summary; and summaries of weight change were not provided (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). The Canadian trial reported nutritional status as weight and BMI z scores (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>Antibiotic use was reported in two trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>), but the data were summarized differently: as average days oral antibiotic treatment per participant per year in the piroxicam trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>); and as change in the percentage using oral, inhaled or intravenous antibiotics over the period of the Konstan trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). The Canadian trial reported the use of oral or inhaled antibiotics (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>QoL measures were not reported in any of the trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>Of the adverse outcomes specified, abdominal pain was reported in four trials; epistaxis (nose bleeds) in two trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>); conjunctivitis in two trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) occult blood, decrease in stool frequency in one trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>); nausea, diarrhoea, gastritis, epigastric pain, reflux esophagitis, hepatitis, vomiting tinnitus, reactive arthritis, elevated liver enzymes and gastro‐intestinal bleeds in one trial (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). None of the trials reported haemorrhagic stroke, dyspepsia, rash, fever, bronchospasm or fluid retention. </p> <p>Dropout rates and number of participants completing the trial were reported in four trials. Compliance was only reported in the ibuprofen trials, in which it was monitored by pill counts or plasma levels or both (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Deaths were reported in the piroxicam trial only (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> </section> <section id="CD001505-sec-0075"> <h4 class="title">Excluded studies</h4> <p>A total of 10 trials are excluded (<a href="./references#CD001505-bbs2-0005" title="ChmielJF , KonstanMW , AccursoFJ , LympJ , Mayer‐HamblettN , VanDevanterDR , et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis2015;14(6):720‐6. [CFGD Register: PI218b] ChmielJF , KonstanMW , LympJ , Mayer‐HamblettN , HilliardKA , AccursoFJ , et al. Assessment of induced sputum as a tool to evaluate anti‐inflammatory agents in CF. Pediatric Pulmonology2007;42 Suppl 30:228. [CFGD Register: PI218a] ">Chmiel 2007</a>; <a href="./references#CD001505-bbs2-0006" title="GonzalezV , SieglerN , CrandallR , MckieKT , ForseenC , Rodriguez‐MiguelezP , et al. Acute sildenafil treatment improves exercise capacity in patients with cystic fibrosis. FASEB Journal. Experimental Biology Abstracts2018;32(Supplement 1):no pagination. [Abstract No.: 853.5; CFGD Register: IB124] ">Gonzalez 2018</a>; <a href="./references#CD001505-bbs2-0007" title="HuntK , StClairC , Curran‐EverettD , SolomonGM , SaavedraMT , NickJA , et al. CFTR effects of oral sildenafil in combination with lumacaftor/ivacaftor in adults with CF. Pediatric Pulmonology2017;52 Suppl 47:322. [CFGD Register: IB117] ">Hunt 2017</a>; <a href="./references#CD001505-bbs2-0008" title="KovalevaLF , GuembitskaiaTE , GorbenkoIA , AleshinYuN . Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:155. [CFGD Register: IB91] ">Kovaleva 2000</a>; <a href="./references#CD001505-bbs2-0009" title="NoritakeD , HenJ , DolanTF . Effects of aspirin on pulmonary function in patients with cystic fibrosis. Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:144. [CFGD Register: IB4b] NoritakeDT , HenJ , LeoL , DolanTF . The influence of aspirin on lung function in cystic fibrosis. Connecticut Medicine1982;46:574‐6. [CFGD Register: IB4a] ">Noritake 1982</a>; <a href="./references#CD001505-bbs2-0010" title="PukhalskyAL , ShmarinaGV , KapranovNI , KakorovtsevaSN , PukhalskayaD , KashirskajaNJ . Anti‐inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediator of Inflammation2004;13(2):111‐7. [CENTRAL: 997725; CFGD Register: IB44c; CRS: 5500125000000705; PUBMED: 15203552] PukhalskyAL , ShmarinaGV , KaproanovNI , KashirskajaNJ , KokarovtsevaSN , ShabalovaLA . Increase of the sputumneutrophil elastase activity in a paradoxical effect of the successful lung disease treatment in cystic fibrosis. Pediatric Pulmonology2001;32 (Suppl 22):274. [CFGD Register: IB44b] ShmarinaGV , PukhalskyAL , KashirskajaNJ . Anti‐inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase‐2 inhibitor) and clarithromycin (14‐membrered ring macrolide antibiotic). European Respiratory Journal. 2004; Vol. Suppl 48:P3758. [CFGD Register: IB44a] ">Shmarina 2004</a>; <a href="./references#CD001505-bbs2-0011" title="AhujaS , SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , et al. CTX‐ 4430 in a phase 1 clinical trial in cystic fibrosis patients. Pediatric Pulmonology2015;50 Suppl 41:299. [Abstract no. : 287; CENTRAL: 1092202; CFGD Register: IB107d; CRS: 5500135000001391] SpringmanE , BhattL , GrosswaldR , PhilpotE . Pharmacokinetic and pharmacodynamic profile of CTX ‐4430 in two phase 1 studies. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 127; CENTRAL: 1077210; CFGD Register: IB107c; CRS: 5500135000001299] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Inflammation Research2015;64(2 Suppl 1):S206‐7. [Abstract no.: B261; CENTRAL: 1107950; CFGD Register: IB107e; CRS: 5500050000000292; EMBASE: 71973697] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 126; CENTRAL: 1077211; CFGD Register: IB107b; CRS: 5500135000001300] SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Pediatric Pulmonology2014;49 Suppl 38:311. [Abstract no.: 267; CENTRAL: 1012389; CFGD Register: IB107a; CRS: 5500131000000163] ">Springman 2014</a>; <a href="./references#CD001505-bbs2-0012" title="Taylor‐CousarJL , HuntKC , ClairC , EverettDC , NickJA , SaavedraMT , AbmanSH . A randomised controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis. Journal of Cystic Fibrosis2018;17 Suppl 3:S26. [Abstract no.: WS14.5; CFGD Register: IB121a] Tayor‐CousarJL , HuntKC , St. ClairC , EverettD , FensterB , NickJA , et al. Sildenafil improves cardiac performance, exercise intolerance and quality of life in moderate to severe cf lung disease. Pediatric Pulmonology2018;53 Suppl 2:226‐7. [Abstract no.: 212; CFGD Register: IB121b] ">Taylor‐Cousar 2017</a>; <a href="./references#CD001505-bbs2-0013" title="VargasMH , Del‐Razo‐RodriguezR , Lopez‐GarciaA , Lezana‐FernandezJL , ChavezJ , FuruyaMEY , et al. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial. BMC Pulmonary Medicine2017;17(1):206. [CFGD Register: IB125a; DOI: 10.1186/s12890‐017‐0528‐x] ">Vargas 2017</a>; <a href="./references#CD001505-bbs2-0014" title="CallahanKA , Diener‐WestM , SchoeberleinC , BoyleMP , ZeitlinPL . Preliminary safety profile of digitoxin to treat CF. Pediatric Pulmonology2014;49(Suppl 38):293. [Abstract no.: 219; CFGD Register: IB109b] LeeS , WalkerD , ZeitlinP . Nasal microarray analysis in CF subjects taking digitoxin. Pediatric Pulmonology2015;50 Suppl 41:292. [Abstract no.: 267; CFGD Register: IB109c] ZeitlinP , Diener‐WestM , CallahanKA , PollardB , LechtzinN , BoyleMP . Phase II study of digitoxin for CF. Pediatric Pulmonology2015;50 Suppl 41:268. [Abstract no.: 207; CFGD Register: IB109d] ZeitlinPL . Phase II study of digitoxin to treat cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00782288 (first posted 31 October 2008). [CFGD Register: IB109a] ZeitlinPL , Diener‐WestM , CallahanKA , LeeS , TalbotCCJr , PollardB , et al. Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding. Annals of the American Thoracic Society2017;14(2):220‐9. [CFGD Register: IB109e; ] ">Zeitlin 2017</a>). One trial (with two reports) was ineligible for inclusion as it reported a single‐dose challenge with aspirin (<a href="./references#CD001505-bbs2-0009" title="NoritakeD , HenJ , DolanTF . Effects of aspirin on pulmonary function in patients with cystic fibrosis. Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:144. [CFGD Register: IB4b] NoritakeDT , HenJ , LeoL , DolanTF . The influence of aspirin on lung function in cystic fibrosis. Connecticut Medicine1982;46:574‐6. [CFGD Register: IB4a] ">Noritake 1982</a>). Two trials were ineligible due to insufficient duration; in one the treatment duration was only 15 days (<a href="./references#CD001505-bbs2-0011" title="AhujaS , SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , et al. CTX‐ 4430 in a phase 1 clinical trial in cystic fibrosis patients. Pediatric Pulmonology2015;50 Suppl 41:299. [Abstract no. : 287; CENTRAL: 1092202; CFGD Register: IB107d; CRS: 5500135000001391] SpringmanE , BhattL , GrosswaldR , PhilpotE . Pharmacokinetic and pharmacodynamic profile of CTX ‐4430 in two phase 1 studies. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 127; CENTRAL: 1077210; CFGD Register: IB107c; CRS: 5500135000001299] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Inflammation Research2015;64(2 Suppl 1):S206‐7. [Abstract no.: B261; CENTRAL: 1107950; CFGD Register: IB107e; CRS: 5500050000000292; EMBASE: 71973697] SpringmanE , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Journal of Cystic Fibrosis2015;14 Suppl 1:S90. [Abstract no.: 126; CENTRAL: 1077211; CFGD Register: IB107b; CRS: 5500135000001300] SpringmanEB , GrosswaldR , PhilpotE , MacGregorG , HorsleyA , BiltonD , et al. A phase 1 clinical study of CTX‐4430 in cystic fibrosis patients. Pediatric Pulmonology2014;49 Suppl 38:311. [Abstract no.: 267; CENTRAL: 1012389; CFGD Register: IB107a; CRS: 5500131000000163] ">Springman 2014</a>) and the second only followed participants for a period of four weeks (<a href="./references#CD001505-bbs2-0005" title="ChmielJF , KonstanMW , AccursoFJ , LympJ , Mayer‐HamblettN , VanDevanterDR , et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis2015;14(6):720‐6. [CFGD Register: PI218b] ChmielJF , KonstanMW , LympJ , Mayer‐HamblettN , HilliardKA , AccursoFJ , et al. Assessment of induced sputum as a tool to evaluate anti‐inflammatory agents in CF. Pediatric Pulmonology2007;42 Suppl 30:228. [CFGD Register: PI218a] ">Chmiel 2007</a>). Six trials did not employ an oral NSAID (<a href="./references#CD001505-bbs2-0006" title="GonzalezV , SieglerN , CrandallR , MckieKT , ForseenC , Rodriguez‐MiguelezP , et al. Acute sildenafil treatment improves exercise capacity in patients with cystic fibrosis. FASEB Journal. Experimental Biology Abstracts2018;32(Supplement 1):no pagination. [Abstract No.: 853.5; CFGD Register: IB124] ">Gonzalez 2018</a>; <a href="./references#CD001505-bbs2-0007" title="HuntK , StClairC , Curran‐EverettD , SolomonGM , SaavedraMT , NickJA , et al. CFTR effects of oral sildenafil in combination with lumacaftor/ivacaftor in adults with CF. Pediatric Pulmonology2017;52 Suppl 47:322. [CFGD Register: IB117] ">Hunt 2017</a>; <a href="./references#CD001505-bbs2-0008" title="KovalevaLF , GuembitskaiaTE , GorbenkoIA , AleshinYuN . Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:155. [CFGD Register: IB91] ">Kovaleva 2000</a>; <a href="./references#CD001505-bbs2-0012" title="Taylor‐CousarJL , HuntKC , ClairC , EverettDC , NickJA , SaavedraMT , AbmanSH . A randomised controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis. Journal of Cystic Fibrosis2018;17 Suppl 3:S26. [Abstract no.: WS14.5; CFGD Register: IB121a] Tayor‐CousarJL , HuntKC , St. ClairC , EverettD , FensterB , NickJA , et al. Sildenafil improves cardiac performance, exercise intolerance and quality of life in moderate to severe cf lung disease. Pediatric Pulmonology2018;53 Suppl 2:226‐7. [Abstract no.: 212; CFGD Register: IB121b] ">Taylor‐Cousar 2017</a>; <a href="./references#CD001505-bbs2-0013" title="VargasMH , Del‐Razo‐RodriguezR , Lopez‐GarciaA , Lezana‐FernandezJL , ChavezJ , FuruyaMEY , et al. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial. BMC Pulmonary Medicine2017;17(1):206. [CFGD Register: IB125a; DOI: 10.1186/s12890‐017‐0528‐x] ">Vargas 2017</a>; <a href="./references#CD001505-bbs2-0014" title="CallahanKA , Diener‐WestM , SchoeberleinC , BoyleMP , ZeitlinPL . Preliminary safety profile of digitoxin to treat CF. Pediatric Pulmonology2014;49(Suppl 38):293. [Abstract no.: 219; CFGD Register: IB109b] LeeS , WalkerD , ZeitlinP . Nasal microarray analysis in CF subjects taking digitoxin. Pediatric Pulmonology2015;50 Suppl 41:292. [Abstract no.: 267; CFGD Register: IB109c] ZeitlinP , Diener‐WestM , CallahanKA , PollardB , LechtzinN , BoyleMP . Phase II study of digitoxin for CF. Pediatric Pulmonology2015;50 Suppl 41:268. [Abstract no.: 207; CFGD Register: IB109d] ZeitlinPL . Phase II study of digitoxin to treat cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00782288 (first posted 31 October 2008). [CFGD Register: IB109a] ZeitlinPL , Diener‐WestM , CallahanKA , LeeS , TalbotCCJr , PollardB , et al. Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding. Annals of the American Thoracic Society2017;14(2):220‐9. [CFGD Register: IB109e; ] ">Zeitlin 2017</a>); three used a vasoactive agent (<a href="./references#CD001505-bbs2-0006" title="GonzalezV , SieglerN , CrandallR , MckieKT , ForseenC , Rodriguez‐MiguelezP , et al. Acute sildenafil treatment improves exercise capacity in patients with cystic fibrosis. FASEB Journal. Experimental Biology Abstracts2018;32(Supplement 1):no pagination. [Abstract No.: 853.5; CFGD Register: IB124] ">Gonzalez 2018</a>; <a href="./references#CD001505-bbs2-0007" title="HuntK , StClairC , Curran‐EverettD , SolomonGM , SaavedraMT , NickJA , et al. CFTR effects of oral sildenafil in combination with lumacaftor/ivacaftor in adults with CF. Pediatric Pulmonology2017;52 Suppl 47:322. [CFGD Register: IB117] ">Hunt 2017</a>; <a href="./references#CD001505-bbs2-0012" title="Taylor‐CousarJL , HuntKC , ClairC , EverettDC , NickJA , SaavedraMT , AbmanSH . A randomised controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis. Journal of Cystic Fibrosis2018;17 Suppl 3:S26. [Abstract no.: WS14.5; CFGD Register: IB121a] Tayor‐CousarJL , HuntKC , St. ClairC , EverettD , FensterB , NickJA , et al. Sildenafil improves cardiac performance, exercise intolerance and quality of life in moderate to severe cf lung disease. Pediatric Pulmonology2018;53 Suppl 2:226‐7. [Abstract no.: 212; CFGD Register: IB121b] ">Taylor‐Cousar 2017</a>), one compared a mucolytic combined with nebulizer therapy to nebulizer therapy alone (<a href="./references#CD001505-bbs2-0008" title="KovalevaLF , GuembitskaiaTE , GorbenkoIA , AleshinYuN . Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:155. [CFGD Register: IB91] ">Kovaleva 2000</a>), one evaluated oral glycine (<a href="./references#CD001505-bbs2-0013" title="VargasMH , Del‐Razo‐RodriguezR , Lopez‐GarciaA , Lezana‐FernandezJL , ChavezJ , FuruyaMEY , et al. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial. BMC Pulmonary Medicine2017;17(1):206. [CFGD Register: IB125a; DOI: 10.1186/s12890‐017‐0528‐x] ">Vargas 2017</a>) and one employed digitoxin (<a href="./references#CD001505-bbs2-0014" title="CallahanKA , Diener‐WestM , SchoeberleinC , BoyleMP , ZeitlinPL . Preliminary safety profile of digitoxin to treat CF. Pediatric Pulmonology2014;49(Suppl 38):293. [Abstract no.: 219; CFGD Register: IB109b] LeeS , WalkerD , ZeitlinP . Nasal microarray analysis in CF subjects taking digitoxin. Pediatric Pulmonology2015;50 Suppl 41:292. [Abstract no.: 267; CFGD Register: IB109c] ZeitlinP , Diener‐WestM , CallahanKA , PollardB , LechtzinN , BoyleMP . Phase II study of digitoxin for CF. Pediatric Pulmonology2015;50 Suppl 41:268. [Abstract no.: 207; CFGD Register: IB109d] ZeitlinPL . Phase II study of digitoxin to treat cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00782288 (first posted 31 October 2008). [CFGD Register: IB109a] ZeitlinPL , Diener‐WestM , CallahanKA , LeeS , TalbotCCJr , PollardB , et al. Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding. Annals of the American Thoracic Society2017;14(2):220‐9. [CFGD Register: IB109e; ] ">Zeitlin 2017</a>). Finally, one trial was previously included, but after contact with the study investigators, has now been excluded as it was not randomised (<a href="./references#CD001505-bbs2-0010" title="PukhalskyAL , ShmarinaGV , KapranovNI , KakorovtsevaSN , PukhalskayaD , KashirskajaNJ . Anti‐inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediator of Inflammation2004;13(2):111‐7. [CENTRAL: 997725; CFGD Register: IB44c; CRS: 5500125000000705; PUBMED: 15203552] PukhalskyAL , ShmarinaGV , KaproanovNI , KashirskajaNJ , KokarovtsevaSN , ShabalovaLA . Increase of the sputumneutrophil elastase activity in a paradoxical effect of the successful lung disease treatment in cystic fibrosis. Pediatric Pulmonology2001;32 (Suppl 22):274. [CFGD Register: IB44b] ShmarinaGV , PukhalskyAL , KashirskajaNJ . Anti‐inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase‐2 inhibitor) and clarithromycin (14‐membrered ring macrolide antibiotic). European Respiratory Journal. 2004; Vol. Suppl 48:P3758. [CFGD Register: IB44a] ">Shmarina 2004</a>). </p> <section id="CD001505-sec-0076"> <h5 class="title">Studies awaiting classification</h5> <p>One phase 2 RCT is currently awaiting classification (<a href="./references#CD001505-bbs2-0015" title="ElbornJ , Taylor‐CousarJL , RoweSM , GrosswaldR , MershonJ , SpringmanE , et al. A phase 2 trial (EMPIRE CF) of a novel anti‐inflammatory molecule, acebilustat, in patients with cystic fibrosis. Pediatric Pulmonology2018;53 Suppl 2:227‐8. [Abstract no.: 214; CFGD Register: IB122c] ElbornJS , AhujaS , MershonJ , SpringmanE , RoweSM . Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF). Journal of Cystic Fibrosis2018;17(Suppl 3):S27. [CFGD Register: IB122a] ElbornJS , AhujaS , SpringmanE , MershonJ , GrosswaldR , RoweSM . EMPIRE‐CF: a phase II randomized placebo‐controlled trial of once‐daily, oral acebilustat in adult patients with cystic fibrosis ‐ Study design and patient demographics. Contemporary Clinical Trials2018;72:86‐94. [CFGD Register: IB122b] ">EMPIRE 2018</a>). This is a double‐blind RCT being conducted at 75 locations across North America and Europe. It has a parallel design comparing two doses of once‐daily acebilustat (50 mg or 100 mg) to placebo. Acebilustat is an oral molecule with anti‐inflammatory activity through the inhibition of LTA4 hydrolase and modulation of LTB4. Investigators have enrolled 200 participants aged between 18 and 30 years old, whose FEV<sub>1</sub> % predicted results are at least 50% and who have experienced at least one exacerbation in the past year. To date, information is only available which summarises the trial protocol and participant characteristics; we await full publication before including or excluding this trial (<a href="./references#CD001505-bbs2-0015" title="ElbornJ , Taylor‐CousarJL , RoweSM , GrosswaldR , MershonJ , SpringmanE , et al. A phase 2 trial (EMPIRE CF) of a novel anti‐inflammatory molecule, acebilustat, in patients with cystic fibrosis. Pediatric Pulmonology2018;53 Suppl 2:227‐8. [Abstract no.: 214; CFGD Register: IB122c] ElbornJS , AhujaS , MershonJ , SpringmanE , RoweSM . Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF). Journal of Cystic Fibrosis2018;17(Suppl 3):S27. [CFGD Register: IB122a] ElbornJS , AhujaS , SpringmanE , MershonJ , GrosswaldR , RoweSM . EMPIRE‐CF: a phase II randomized placebo‐controlled trial of once‐daily, oral acebilustat in adult patients with cystic fibrosis ‐ Study design and patient demographics. Contemporary Clinical Trials2018;72:86‐94. [CFGD Register: IB122b] ">EMPIRE 2018</a>). </p> </section> <section id="CD001505-sec-0077"> <h5 class="title">Ongoing studies</h5> <p>In addition two trials were identified from a search of the clinicaltrials.gov website, both trials are ongoing and details have not been reported to date (<a href="./references#CD001505-bbs2-0016" title="NCT03265288 . Study of LAU‐7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD). clinicaltrials.gov/ct2/show/NCT03265288 (first posted 29 August 2017). ">APPLAUD 2017</a>; <a href="./references#CD001505-bbs2-0017" title="NCT03451045 . Trial to evaluate efficacy and safety of lenabasum in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03451045 (first posted 01 March 2018). ">NCT03451045</a>). </p> <p>The first of these is a phase 2 double‐blind RCT being undertaken at 25 locations in the USA and Canada (<a href="./references#CD001505-bbs2-0016" title="NCT03265288 . Study of LAU‐7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD). clinicaltrials.gov/ct2/show/NCT03265288 (first posted 29 August 2017). ">APPLAUD 2017</a>). It commenced in October 2018 and is due to complete December 2019. A total of 136 eligible adults with CF will be randomized to receive 300 mg LAU‐7b or placebo in a 1:1 ratio. The treatment regimen will consist of six consecutive "dosing cycles" of 21 days each, spaced by drug‐free periods of seven days. Participation in the trial will last about seven months. The primary outcomes are the absolute change in FEV<sub>1</sub> % predicted, safety and tolerability; secondary outcomes include further measures of lung function, frequency of and time to first pulmonary exacerbation, anthropometric measures, <i>P aeruginosa</i> density and QoL (<a href="./references#CD001505-bbs2-0016" title="NCT03265288 . Study of LAU‐7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD). clinicaltrials.gov/ct2/show/NCT03265288 (first posted 29 August 2017). ">APPLAUD 2017</a>). </p> <p>The second ongoing trial is evaluating the efficacy and safety of lenabasum, an oral small molecule which has been shown to be active in animal models of lung infection and inflammation in CF (<a href="./references#CD001505-bbs2-0017" title="NCT03451045 . Trial to evaluate efficacy and safety of lenabasum in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03451045 (first posted 01 March 2018). ">NCT03451045</a>). This trial is a phase 2 double‐blind RCT of parallel design being conducted at approximately 100 sites in North America, Europe, and Australia. It commenced December 2017 and is still recruiting (trial due to complete November 2019). Investigators plan to enrol approximately 415 participants aged 12 years and older and weighing at least 40 kg with a baseline FEV<sub>1</sub> % predicted of between 40% and 100%. Investigators will compare two twice‐daily doses of lenabasum (20 mg or 5 mg) to twice‐daily placebo for 28 weeks. Outcomes planned are pulmonary exacerbations, QoL (Cystic Fibrosis Questionnaire‐Revised (CFQ‐R)), lung function (FEV<sub>1</sub> % predicted) and adverse events (<a href="./references#CD001505-bbs2-0017" title="NCT03451045 . Trial to evaluate efficacy and safety of lenabasum in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03451045 (first posted 01 March 2018). ">NCT03451045</a>). </p> </section> </section> </section> <section id="CD001505-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD001505-sec-0079"> <h4 class="title">Allocation</h4> <p>The method used to generate the random sequence and the concealment of allocation were assigned to one of three categories: adequate; unclear; or inadequate; these corresponded to a low, unclear or high risk of bias respectively. </p> <section id="CD001505-sec-0080"> <h5 class="title">Generation of sequence</h5> <p>The method used to generate the random sequence was adequate in all three ibuprofen trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the earlier Konstan trial, randomisation was based upon a computer‐generated randomisation sequence (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the later Konstan trial, randomisation was carried out with permuted blocks of four participants each stratified by age (under 13 years, 13 to 18 years and 19 years or over) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the Lands trial, participants were allocated using a predefined block‐randomisation schedule (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). This corresponded to a low risk of bias for generation of the randomisation sequence in each of these trials. </p> <p>In the piroxicam trial, while the process was described as random in the paper, the randomisation method was unclear (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). This led to the risk of bias for generation of sequence being judged to be unclear. </p> </section> <section id="CD001505-sec-0081"> <h5 class="title">Concealment of allocation</h5> <p>Concealment of allocation was adequate in all three ibuprofen trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the earlier Konstan trial, the randomisation sequence was provided by the pharmaceutical company (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the later Konstan trial, only the pharmacologist and pharmacist were privy to the allocation (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the Canadian trial, a central pharmacy coded and shipped the tablets to the participating centers; the code was broken by the central pharmacy only on request from the Safety and Monitoring Committee (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). This corresponds to a low risk of bias in these trials due to the concealment of allocation. </p> <p>Concealment of allocation was not discussed and the risk of bias is therefore unclear in the piroxicam trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> </section> <section id="CD001505-sec-0082"> <h4 class="title">Blinding</h4> <p>Reporting of double blinding was recorded as either present or absent.</p> <p>Four trials were described as double blinded. In the earlier Konstan trial the pharmaceutical company provided the clinics with identical‐appearing placebo tablets (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the later Konstan trial, the placebo tablets were again identical in appearance to the ibuprofen tablets (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Lands states that participants, care‐givers and study personnel were all blinded to treatment assignment (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Sordelli describes the placebo tablets as being "indistinguishable" from the piroxicam tablets (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Therefore we judged the risk of bias from blinding to be low in four of the five included trials. </p> </section> <section id="CD001505-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>The reported 'intention‐to‐treat' analysis was defined as complete; or analysed with less than 15% of participants excluded; or analysed with more than 15% of participants excluded. </p> <p>In two of the ibuprofen trials, analysis was based on intention‐to‐treat (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>), while in the other there were less than 15% of participants excluded (three participants) (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). These three withdrawals were due to poor venous access, behavioural problems and difficulty in transport to follow up trial visits. We therefore judged the risk of bias due to incomplete outcome data to be low in these three trials. </p> <p>More than 15% of participants were excluded from the intention‐to‐treat analysis (n = 8) (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Four participants from the treatment group and four from the control group did not complete the study. Reasons for exclusion included abdominal pain, hematemesis, hepatic dysfunction and acute respiratory exacerbation. Risk of bias was also low as withdrawals described and were equal across groups. </p> </section> <section id="CD001505-sec-0084"> <h4 class="title">Selective reporting</h4> <p>In two studies we did not identify any selective reporting as all the listed outcomes measured were reported in the results section of the paper (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Thus we judged these trials to be at a low risk of bias from selective reporting. It should be noted that in Konstan's ibuprofen trials, the trial investigators monitored a large number of potential adverse effects of ibuprofen but reporting was confined to those considered to be most important and findings which were not statistically significant were not reported; we therefore judge there to be a high risk of bias from selective reporting in these two trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). </p> </section> <section id="CD001505-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>All four studies reported adverse events (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> <p>The later Konstan trial was funded by the Cystic Fibrosis Foundation and the National Institutes of Health (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) and the Canadian trial specifically states that the funders did not have a role in the analysis or publication of results (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> </section> <section id="CD001505-sec-0086"> <h3 class="title" id="CD001505-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD001505-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</a> </p> <p>The evidence grades stated for the outcomes reported in the summary of findings table are based on GRADE (<a href="#CD001505-sec-0054">Data collection and analysis</a>) and further details are provided in the summary of findings table (<a href="./full#CD001505-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD001505-sec-0087"> <h4 class="title">Oral non‐steroidal anti‐inflammatory drug versus placebo</h4> <section id="CD001505-sec-0088"> <h5 class="title">Primary outcome</h5> <section id="CD001505-sec-0089"> <h6 class="title">1. Objective measures of lung function</h6> <p>In the second Konstan trial and the Canadian trial measures of lung function were summarized as the within‐participant annual rates of change over the trial period (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the Konstan trial differences in rates of change for FVC, FEV<sub>1</sub> and FEF<sub>25%‐75%</sub> included age as a covariate (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Like the Konstan trial, the Canadian trial used mixed‐model analysis adjusting for the correlated nature of the repeated measurements (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). It is important to note that participants in the Konstan trial ranged in age from 5 to 39 years (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>), whereas those in the Trans Canadian trial ranged from 6 to18 years (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). The other ibuprofen trial only measured FEV<sub>1</sub>, but did not report data we could enter into the analysis (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the piroxicam trial, FEV<sub>1</sub>, FVC and FEF<sub>25%‐75%</sub> were summarised as the group mean and standard errors at each of five visits during the study period and therefore could not be directly compared to the other studies (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Participants completing the study were also classified according to whether their respiratory function was 'not worse' (defined as 10% increase in baseline absolute value of one or more of FEV<sub>1</sub>, FVC or FEF<sub>25%‐75%</sub>) or 'worse' (less than 10% increase). </p> <section id="CD001505-sec-0090"> <p><b>a. FEV<sub>1</sub> </b></p> <p>We were able to combine data from two ibuprofen trials in the meta‐analysis (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Overall, the meta‐analysis results show a statistically significant positive influence of high‐dose ibuprofen on the rate of change of % predicted FEV<sub>1</sub>, MD 1.32% (95% CI 0.21 to 2.42) (<a href="./references#CD001505-fig-0001" title="">Analysis 1.1</a>) (moderate‐quality evidence). When the trials were considered individually, the second Konstan trial found participants treated with ibuprofen experienced a slower annualized rate of decline in % predicted FEV<sub>1</sub> compared to the placebo group, MD 1.43% (95% CI ‐0.12 to 2.98), but this was not statistically significant (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). The annual rate of change % predicted FEV<sub>1</sub> in the Canadian trial was also not significantly different between the two treatment groups, but demonstrated a slower decline in the ibuprofen group, MD 1.20% (95% CI ‐0.38 to 2.78) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the first ibuprofen trial, there were no data reported which could be included in the meta‐analysis, but the authors reported no significant change in FEV<sub>1</sub> among those completing treatment over a two‐month period with either ibuprofen or placebo (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). </p> <p>Overall, the post‐hoc analysis of data from two trials split by age showed a statistically significant slower rate of annual decline of % predicted FEV<sub>1</sub> in the ibuprofen group in younger children, MD 1.41% (95% CI 0.03 to 2.80), compared with a non‐significant difference in children aged 13 years and over, MD of 0.75 (95% CI ‐1.02 to 2.52) (<a href="./references#CD001505-fig-0002" title="">Analysis 1.2</a>) (moderate‐quality evidence). In the second Konstan trial the effect of ibuprofen was stronger amongst those starting treatment with ibuprofen before the age of 13 years, MD 2.71% (95% CI 0.60 to 4.82), compared to those aged 13 years and over at start of treatment, MD ‐0.36% (95% CI ‐2.49 to 1.77) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the Canadian trial the difference between the treatment and control groups was not significant in younger children, MD 0.42% (95% CI ‐1.42 to 2.26), but was statistically significant in the older children, MD 3.20% (95% CI 0.04 to 6.36) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> <section id="CD001505-sec-0091"> <p><b>b. FVC</b></p> <p>Again, data from two trials could be combined in the meta‐analysis (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Overall there was a significant difference in annual rate of change % predicted FVC in favour of NSAIDs, MD 1.27% (95% CI 0.26 to 2.28) (<a href="./references#CD001505-fig-0003" title="">Analysis 1.3</a>) (moderate‐quality evidence). Individually, in the second Konstan trial the mean annual decline favoured the ibuprofen group versus the placebo group, but the result was not significant, MD 0.99% (95% CI ‐0.43 to 2.41) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). The Canadian trial found a significant difference in the annual rate of change of % predicted FVC in favour of the ibuprofen group, MD 1.55% (95% CI 0.12 to 2.98) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>As with the FEV<sub>1</sub> data, we compared different age groups in a post‐hoc change to our outcomes. Among participants enrolled before the age of 13, there was stronger evidence in support of ibuprofen for slowing the rate of decline of % predicted FVC, MD 1.32% (95% CI 0.04 to 2.60), compared with the rate of decline in participants aged 13 years or older, MD of 0.78% (95% CI ‐0.71 to 2.27). In the under‐13 age group, Konstan showed a significant difference in favour of ibuprofen, MD 2.03% (95% CI 0.10 to 3.96), but the results from Lands were non‐significant, MD 0.76% (95% CI ‐0.95 to 2.47) (<a href="./references#CD001505-fig-0004" title="">Analysis 1.4</a>). Conversely, in the over‐13 age group, Konstan showed a non‐significant result, MD ‐0.47% (95% CI ‐2.27 to 1.33), but Lands demonstrated a significant result in favour of ibuprofen, MD 3.48% (95% CI 0.83 to 6.13) (<a href="./references#CD001505-fig-0004" title="">Analysis 1.4</a>) (moderate‐quality evidence). </p> </section> <section id="CD001505-sec-0092"> <p><b>c. FEF<sub>25%‐75%</sub> </b></p> <p>Similar trends were observed for the annual rate of decline for % predicted FEF<sub>25%‐75%</sub> (<a href="./references#CD001505-fig-0005" title="">Analysis 1.5</a>); the overall result from both trials for all age groups combined was in favour of ibuprofen, MD 1.80% (95% CI 0.16 to 3.44), although both trials individually showed non‐significant results; MD 1.92% (95% CI ‐0.10 to 3.94) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) and MD 1.56% (95% CI ‐1.28 to 4.40) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the post‐hoc analysis stratified by age, the overall difference between the groups was non‐significant in both age groups; for under 13 years at randomisation, MD 2.03% (95% CI ‐0.09 to 4.16) and for 13 years and over, MD 1.28% (95% CI ‐1.22 to 3.79) (<a href="./references#CD001505-fig-0006" title="">Analysis 1.6</a>). Within these groups, Konstan showed a significant difference in the under‐13 age group, MD 2.90% (95% CI 0.20 to 5.60), but Lands showed a non‐significant result, MD 0.62% (95% CI ‐2.83 to 4.07); and both trials showed non‐significant results for the older subgroup, MD 0.49% (95% CI ‐2.35 to 3.33) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) and MD 4.03% (95% CI ‐1.26 to9.32) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> </section> </section> </section> <section id="CD001505-sec-0093"> <h5 class="title">Secondary outcomes</h5> <section id="CD001505-sec-0094"> <h6 class="title">1. Treatment with intravenous antibiotics</h6> <p>Intravenous antibiotic usage was reported in only one trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In this trial, a higher percentage of participants in the ibuprofen arm had received intravenous antibiotics in the 12 months preceding randomisation compared with the placebo group (27% versus 14% respectively). In the final 12 months (Year Four) of the trial, this percentage was similar in the ibuprofen arm (29%), but markedly increased in the placebo arm (37%). Within the trial report, changes in the frequency of concomitant therapy with intravenous antibiotics were compared using categorical‐data modelling, a method which cannot be replicated here without access to individual patient data. Thus a data table was not compared for this outcome, although from this one trial long‐term use of high dose ibuprofen appears to be associated with less use of intravenous antibiotic usage over a 12‐month period. Inhaled antibiotic use was not recorded in the Canadian Trial, and no differences were observed in the concomitant use of inhaled and oral antibiotics (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Participants treated with piroxicam did not require more antibiotics than those treated with placebo in the Sordelli trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Antibiotic use was not reported in the first Konstan trial (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). </p> </section> <section id="CD001505-sec-0095"> <h6 class="title">2. Number of hospital admissions for respiratory exacerbations</h6> <p>Hospital admissions for respiratory exacerbations were only reported in the Canadian trial: 26% (placebo) versus 20% (ibuprofen); however, the difference between the two groups was not statistically significant Peto OR 0.75 (95% CI 0.34 to 1.65) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) (<a href="./references#CD001505-fig-0007" title="">Analysis 1.7</a>). </p> <p>The percentage of participants requiring at least one hospital admission for any reason during the trial period were reported for all four trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a><a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). In the first Konstan trial, one participant in the placebo group was hospitalised (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>). In the second ibuprofen trial by Konstan, 21 participants (51%) in the ibuprofen arm were hospitalised during the course of the trial, compared with 26 (60%) in the control arm (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the Canadian trial admission rates were lower in the ibuprofen group 18 (27%) versus the placebo group 25 (36%), but the difference was not statistically significant (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the piroxicam trial, seven participants (35%) in the piroxicam arm were admitted to hospital compared with 11 (52%) in the control arm (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). Combining these results in the analysis, overall there was no significant difference in the number of admissions in the ibuprofen group compared to the placebo group, Peto OR 0.64 (95 % CI 0.39 to 1.05) (<a href="./references#CD001505-fig-0008" title="">Analysis 1.8</a>) (moderate‐quality evidence). However, the trials were heterogeneous with respect to type of NSAIDs assessed, criteria for inclusion, treatment duration (and hence period at risk for hospital admission), as well as methodological quality. Data were not reported by age group. </p> <p>This analysis does not take into account the number of admissions per participant or the duration of each admission. These data were presented in three trials but in a different format in each, so that the information provided could not be combined (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>; <a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). In one ibuprofen trial, the mean number of hospital days per participant and mean number of admissions per hospital patient were summarised by treatment arm (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Both were lower in the ibuprofen compared with the control group, but were statistically non‐significant, Peto OR 0.62 (95% CI 0.31 to 1.25) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). In the piroxicam trial, median duration of admission was reported to be greater among the control group compared with the intervention group (18 days versus one day respectively). However, this analysis did not take account of individual variation in number and duration of admissions (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> <section id="CD001505-sec-0096"> <h6 class="title">3. Number of days admitted to hospital for respiratory exacerbations</h6> <p>Similarly the number of days spent in hospital for respiratory exacerbations was not reported separately within any trial. Although the number of days spent in hospital for any reason was reported in all four trials, data could not be combined due to the differing summary measures used. In the second Konstan trial, there was no difference reported in number of hospitalisations or days spent in hospital between the groups (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). This did not change when divided into subgroups by age. The Canadian trial reported the absolute number of hospital days in each group 561 (placebo) versus 248 (ibuprofen), as well as the hospitalization rate adjusted for overdisposition; 4.1 days per year (placebo) compared to 1.8 days per year (ibuprofen). Post‐hoc analysis of hospitalization data split by age revealed a significant age trend with older participants having more hospital admissions than younger participants (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). In the Sordelli trial, the number of hospital days per patient days at risk was based on a completed treatment analysis (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). The placebo‐treated group required 301 hospital days of a possible 8609 patient days at risk, while the piroxicam group had 192 of 7920 risk days hospitalised (42% decrease), including one participant admitted four times for a total of 90 days. </p> </section> <section id="CD001505-sec-0097"> <h6 class="title">4. QoL measures</h6> <p>These were not reported in any trial.</p> </section> <section id="CD001505-sec-0098"> <h6 class="title">5. Proportion surviving at six months and one year</h6> <p>Deaths were explicitly reported in only one trial which recruited participants with more severe pulmonary disease than in the other two trials (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). In this trial, two participants (one in each treatment group) died as a consequence of respiratory exacerbations with resistant strains of <i>P aeruginosa</i> (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). The timing of these deaths in relation to enrolment in the trial was not stated: hence data tables for the proportion surviving to six months and one year in this study could not be reported. </p> <p>Although not explicitly reported in the ibuprofen trials, the principal author of two of the trials has confirmed that no death occurred and that all participants were accounted for in these two trials (<a href="./references#CD001505-bbs2-0025" title="KonstanMW . Personal Communication1999. ">Konstan 1999</a>). No deaths were reported in the Canadian Trial (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) (<a href="./references#CD001505-fig-0009" title="">Analysis 1.9</a>). </p> </section> <section id="CD001505-sec-0099"> <h6 class="title">6. Nutritional status</h6> <p>Only the second ibuprofen trial reported change in percentage ideal body weight (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). Ideal body weight was determined on the basis of age, sex and height. Body weight as a percentage of ideal declined among those treated with placebo, whereas those treated with ibuprofen showed no or very little decline, OR 0.99 (95% CI 0.17 to 1.81) (<a href="./references#CD001505-fig-0010" title="">Analysis 1.10</a>). This effect was most marked among those aged less than 13 years; for each year the percentage ideal body weight declined by 1.45% (95% CI 0.33, 2.57) more among control children compared to those treated with ibuprofen (<a href="./references#CD001505-fig-0011" title="">Analysis 1.11</a>). </p> <p>BMI and z scores of weight‐for‐height were only measured in the Canadian trial; neither of these outcomes changed in the two group over the trial period and absolute numbers were not reported (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>Although weight gain was incorporated into an overall assessment of clinical status, it was not reported separately in the piroxicam trial (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). </p> </section> <section id="CD001505-sec-0100"> <h6 class="title">7. Chest X‐ray scores</h6> <p>Chest X‐ray scores were reported in two trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). Overall, the Brasfield chest X‐ray score declined more among the placebo relative to the ibuprofen group MD 0.37 (95% CI ‐0.08 to 0.81), but this decline was not statistically significant (<a href="./references#CD001505-fig-0012" title="">Analysis 1.12</a>). The results for the individual trials were also not significant; MD 0.53 (95% CI ‐0.02 to 1.08) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) and MD 0.07 (95% CI ‐0.68 to 0.82) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). When the chest X‐ray score was stratified by age in the Konstan trial, there was no statistical difference between the ibuprofen and control group in either age group, MD 0.45 (95% CI ‐0.24 to 1.14) and MD 0.63 (95% CI ‐0.30 to 1.56) for participants under 13 years and 13 years and over respectively (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) (<a href="./references#CD001505-fig-0013" title="">Analysis 1.13</a>). </p> </section> <section id="CD001505-sec-0101"> <h6 class="title">8. Adverse effects</h6> <p>Of the adverse outcomes specified, abdominal pain was reported in all trials; epistaxis (nose bleeds) in two trials (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>); conjunctivitis in two trials (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) occult blood, decrease in stool frequency in one trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>); nausea, diarrhoea, gastritis, epigastric pain, reflux esophagitis, hepatitis, vomiting tinnitus, reactive arthritis, elevated liver enzymes and gastro‐intestinal bleeds in one trial (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). None of these data were reported by age group, so it is not possible to assess whether age is an important factor in determining the frequency of adverse effects attributable to NSAIDs. Of the adverse effects listed in the protocol, data were either not available or were not explicitly reported for any of the four eligible trials for the following outcomes: major haemorrhage (i.e. life‐threatening gastrointestinal bleeding or acute haemorrhagic stroke); allergic reactions such as rash, fever or fluid retention. </p> <section id="CD001505-sec-0102"> <p><b>Abdominal pain</b></p> <p>Abdominal pain is a recognised complication of CF as well as of treatment with NSAIDs. Overall, in all three ibuprofen trials, a greater proportion in both treatment groups reported a decrease in abdominal pain (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>); while more participants in the piroxicam trial reported an increase in abdominal pain (<a href="./references#CD001505-bbs2-0004" title="SordelliDO , MacriCN , MaillieAJ . A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia. Pediatric Pulmonology1990;Suppl 5:215. [CFGD Register: IB6b] SordelliDO , MacriCN , MaillieAJ , CerquettiMC . A preliminary study of the effect of anti‐inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology1994;7(2):109‐17. [CFGD Register: IB6b] ">Sordelli 1994</a>). We were able to combine data from two trials looking at the increase in abdominal pain and the analysis showed a non‐significant result in favour of ibuprofen, Peto OR 0.54 (95% CI 0.20 to 1.48) (<a href="./references#CD001505-fig-0014" title="">Analysis 1.14</a>). </p> <p>Only Konstan reported on the decrease in abdominal pain and showed a non‐significant result in favour of ibuprofen, Peto OR 0.81 (95% CI 0.34 to1.92) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) (<a href="./references#CD001505-fig-0015" title="">Analysis 1.15</a>). </p> <p>The Canadian trial also measured and reported the number of gastrointestinal admissions, which did not differ between the two groups; Peto OR 0.52 (95% CI 0.10 to 2.63) (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) (<a href="./references#CD001505-fig-0016" title="">Analysis 1.16</a>). </p> </section> <section id="CD001505-sec-0103"> <p><b>Stool frequency</b></p> <p>Stool frequency was reported in one trial and shown to be less among those treated with ibuprofen, Peto OR 2.92 (95% CI 0.44 to 19.25); however the CIs were very wide (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>) (<a href="./references#CD001505-fig-0017" title="">Analysis 1.17</a>). </p> </section> <section id="CD001505-sec-0104"> <p><b>Other adverse events</b></p> <p>There were no significant differences between treatment and control groups in the proportion of participants with occult blood in the stools, Peto OR 0.36 (95% CI 0.04 to 3.62) (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>) (<a href="./references#CD001505-fig-0018" title="">Analysis 1.18</a>); or in the proportions reporting epistaxis, increase in epistaxis Peto OR 1.27 (95% CI 0.39 to4.10) (<a href="./references#CD001505-fig-0019" title="">Analysis 1.19</a>) and decrease in epistaxis Peto OR 2.08 (95% CI 0.21 to 20.57) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>) (<a href="./references#CD001505-fig-0020" title="">Analysis 1.20</a>); or conjunctivitis, increase in conjunctivitis Peto OR 0.72 (95% CI 0.22 to 2.40) (<a href="./references#CD001505-fig-0021" title="">Analysis 1.21</a>) and decrease in conjunctivitis Peto OR 0.69 (95% CI 0.11 to 4.17) (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>) (<a href="./references#CD001505-fig-0022" title="">Analysis 1.22</a>). </p> <p>The Canadian trial reported on the increase in nausea, Peto OR 2.02 (95% CI 0.21 to 19.78) (<a href="./references#CD001505-fig-0023" title="">Analysis 1.23</a>) and the increase in diarrhoea, Peto OR 1.03 (95% CI 0.06 to 16.62) (<a href="./references#CD001505-fig-0024" title="">Analysis 1.24</a>), neither of which were significant (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>Prophylactic use of medications to protect intestinal mucosa was not routinely recommended in any of the studies, except in the latter part of the Canadian study (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). The use of antacids or H2‐receptor antagonists was similar in both groups during the second Konstan trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). </p> <p>In Konstan's ibuprofen trials, the trial investigators monitored a large number of potential adverse effects of ibuprofen: reporting was confined to those considered to be most important and findings which were not statistically significant were not reported (<a href="./references#CD001505-bbs2-0001" title="KonstanMW , HoppelCL , ChaiB , DavisPB . Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics1991;118(6):956‐64. [CFGD Register: IB5] ">Konstan 1991</a>; <a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001505-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001505-sec-0105"></div> <p>The mechanisms for the beneficial effects of high‐dose ibuprofen have not been clearly elucidated. Commonly the effects have been attributed to the anti‐inflammatory properties of ibuprofen. However, a recent cellular study, using clinically relevant doses, suggests that ibuprofen may exert some of its effect through the activation of the cystic fibrosis transmembrane regulator (<a href="./references#CD001505-bbs2-0030" title="LiJ , XiangYY , YeL , TsuiLC , MacdonaldJF , HuJ , et al. Nonsteroidal anti‐inflammatory drugs upregulate function of wild‐type and mutant CFTR. European Respiratory Journal2008;32(2):334‐43. ">Li 2008</a>). There is increasing biological and scientific evidence to suggest that inflammation is a major contributor to declining lung function in people with CF. The effectiveness of long‐term treatment with anti‐inflammatory agents such as NSAIDs in preventing this decline is therefore of major clinical relevance. Given that measures of lung function, particularly FEV<sub>1</sub>, are the most significant prognostic factors, changes in the rate of decline will have the most significant impact on prognosis. </p> <p>The current management of CF requires those affected and their families to devote a significant effort to complying with physiotherapy, and oral, inhaled or intravenous medication. The extent to which treatment with oral NSAIDs may reduce the need for concomitant treatment or hospital admission is of interest, since this may improve QoL and reduce treatment costs for the individual and the health service. </p> <section id="CD001505-sec-0106"> <h3 class="title" id="CD001505-sec-0106">Summary of main results</h3> <p>The searches identified 17 trials; four are included (287 participants aged five to 39 years; maximum follow‐up of four years), one is currently awaiting classification pending publication of the full trial report and two are ongoing. This systematic review and accompanying meta‐analyses are primarily based on two trials of ibuprofen which contribute the majority of data and allow for meaningful analysis of the rate of decline in FEV<sub>1</sub> and other spirometric indices (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>; <a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). </p> <p>Based on data from 226 participants from these two trials, evidence shows that the use of ibuprofen twice daily probably slows the progression of CF lung disease. A post hoc analysis of data split by age showed a slower rate of annual decline in lung function in the ibuprofen group in younger children than in those aged 13 years and older (<a href="./references#CD001505-fig-0002" title="">Analysis 1.2</a>; <a href="./references#CD001505-fig-0004" title="">Analysis 1.4</a>). The use of ibuprofen can probably slow the rate of decline in lung function in people with mild CF lung disease. The findings were consistent for all lung function outcomes (FEV<sub>1</sub>, FVC and FEF<sub>25%‐75%</sub>). </p> <p>Evidence from this review suggests that there may be important reductions in days spent in hospital for all causes and overall there were fewer hospitalisations and improved chest X‐ray scores in the ibuprofen group. None of the included trials reported on QoL. Unfortunately, the included trials are too small and follow‐up is too short to determine whether treatment with NSAIDs increases survival. Nonetheless, pulmonary function as assessed by FEV<sub>1</sub> is the primary predictor of survival in CF and it is therefore reasonable to assume that maintenance of pulmonary function is an important therapeutic goal in CF. The results do not allow for further comment on an effect on nutritional status, other than what is reported in the Konstan trial (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>), which found weight declined in the placebo group, but not in the ibuprofen group. The rate of change of percentage of ideal body weight was greatest in the under 13 year group receiving NSAIDs, and for the cohort as a whole. </p> <p>Confirming previous studies, the additional information provided by the Trans‐Canadian trial suggests that high‐dose ibuprofen does not result in an increase in abdominal pain, nausea, or diarrhoea (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). This trial did, however, report one case of significant gastrointestinal haemorrhage which led to the introduction of routine prophylactic prescription of H2‐blockers or proton ion pump inhibitors to protect intestinal mucosa. The reported adverse events differed between the studies, but overall did not differ between the treatment and control groups. </p> <p>The results of this review suggest that the beneficial effects of anti‐inflammatory treatment with NSAIDs may be greatest among young children with mild disease, in whom fixed structural damage to the lungs has not yet occurred. The second Konstan trial used the age of 13 years as an arbitrary cut‐off point and found similar results with different age cut‐off points (<a href="./references#CD001505-bbs2-0002" title="KonstanMW . Systemic anti‐inflammatory treatment NSAID. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:L51. [CFGD Register: IB10a] KonstanMW , ByardPJ , HoppelCL , DavisPB . Effect of high‐dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine1995;332(13):848‐54. [CFGD Register: IB10c] KonstanMW , DavisPB , ByardPJ , HoppelCJ . Results of a four‐year, randomized, placebo‐controlled, double‐blind trial of high‐dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology1994;Suppl 10:S6.4. [CFGD Register: IB10b] ">Konstan 1995</a>). </p> </section> <section id="CD001505-sec-0107"> <h3 class="title" id="CD001505-sec-0107">Overall completeness and applicability of evidence</h3> <p>An important consideration is that the existing trials have recruited participants from across a wide age span, and have included young children as well as adults with CF although the effects of NSAID treatment in children aged under five years has not been reported. </p> <p>The trials reporting treatment with ibuprofen employed a high dose, designed to achieve mean peak plasma concentrations of greater than 50 µg/mL, which have been associated with maximal anti‐inflammatory effect. A potentially narrow therapeutic window for ibuprofen may exist as experimental work in animals and humans suggests that low plasma concentrations may be associated with a paradoxical increase in inflammation (<a href="./references#CD001505-bbs2-0023" title="KonstanMW , VargoKM , DavisPB . Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. American Review of Respiratory and Critical Care Medicine1990;141(1):186‐92. ">Konstan 1990</a>; <a href="./references#CD001505-bbs2-0026" title="KonstanMW , KrenickyJE , FinneyMR , KirchnerHL , HilliardKA , HilliardJB , et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. Journal of Pharmacology and Experimental Therapeutics2003;306(3):1086‐91. ">Konstan 2003</a>). Careful pharmacological monitoring was employed in the ibuprofen trials to maintain peak plasma concentrations in the desired range. Further studies are required to determine whether other NSAIDs are associated with this biphasic response. </p> </section> <section id="CD001505-sec-0108"> <h3 class="title" id="CD001505-sec-0108">Quality of the evidence</h3> <p>We judged the evidence to be of moderate quality. We thought the three ibuprofen trials had a good or adequate level of methodological quality with little risk of bias to the results, but used a range of different outcomes and summary measures. Not all outcomes were reported in all trials and the evidence was downgraded once due to a judgement of selective reporting. Additional data may change the CIs and thus change the estimates. We did not have any concerns with regards to risks of bias for the trial comparing piroxicam to placebo. </p> </section> <section id="CD001505-sec-0109"> <h3 class="title" id="CD001505-sec-0109">Potential biases in the review process</h3> <p>The review authors conducted a comprehensive literature search of online journal databases using the Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register and the ongoing online trials databases and also of manual searching of journal conference abstracts. Two authors individually applied the inclusion and exclusion criteria to the identified studies and excluded studies that were not relevant. Included studies were appraised more thoroughly and data extracted independently using a pre‐determined form. The authors assessed the risk of bias of the included studies and if they failed to reach a consensus on the risk of bias, a third author arbitrated. The analyses were undertaken by a statistician (SS). None of the authors have received direct or indirect payments from the companies responsible for the development of any agents included in this review, one of the authors was the principal investigator for one of the included studies (LL). This review has assessed all available published study data. </p> </section> <section id="CD001505-sec-0110"> <h3 class="title" id="CD001505-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>Since NSAIDs are considered a safe medication in children, they have become increasingly available as an over‐the‐counter preparation to young children; however, there is little known about the effects of using high doses for a prolonged period of time. Confirming previous studies, the additional information provided by the most recent Trans‐Canadian trial suggests that high‐dose ibuprofen did not result in an increase in abdominal pain, nausea, or diarrhoea (<a href="./references#CD001505-bbs2-0003" title="LandsLC , CoreyM , MilnerR , KilcullenA , CantinAM . High dose ibuprofen in CF children: the Trans‐Canadian trial. Pediatric Pulmonology2002;34(Suppl 24):276. [CFGD Register: IB38a] LandsLC , MilnerR , CantainAM , MansonD , CoreyM . High‐dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics2007;151(3):249‐54. [CFGD Register: IB38b] ">Lands 2007</a>). The most recent trial did, however, report one case of significant gastrointestinal haemorrhage which led to the introduction of routine prophylactic prescription of H2‐blockers or proton ion pump inhibitors to protect intestinal mucosa. The effectiveness of this protective strategy has not been documented. Furthermore, four cases of transient renal failure among children being treated concurrently with ibuprofen and intravenous aminoglycosides have been reported, emphasising the importance of adequately assessing adverse effects in the context of other drug therapies (<a href="./references#CD001505-bbs2-0029" title="KovesiTA , SwartzR , MacDonaldN . Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis (letter). New England Journal of Medicine1998;338(1):65‐6. ">Kovesi 1998</a>). More recently, Bertenshaw has retrospectively shown acute renal failure among individuals who were treated concurrently with aminoglycosides and NSAIDs (<a href="./references#CD001505-bbs2-0018" title="BertenshawC , WatsonA , LewisS , SmythA . A survey of acute renal failure in cystic fibrosis patients in the United Kingdom. http://thorax.bmj.com/ (accessed 30 January 2007). ">Bertenshaw 2007</a>), which provides further evidence of an interaction between NSAIDs and intravenous aminoglycosides that may have important clinical implications. </p> <p>In 2007, a review of people on the US Cystic Fibrosis Foundation Patient Registry was undertaken to evaluate the effect of high‐dose ibuprofen (<a href="./references#CD001505-bbs2-0027" title="KonstanMW , SchluchterMD , XueW , DavisPB . Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2007;176(11):1084‐9. ">Konstan 2007</a>). Data were evaluated from individuals with an initial age of 6 to 17 years and an FEV<sub>1</sub> below 60% predicted; the period covered was 1996 to 2002. There was a significant reduction in the rate of decline of FEV<sub>1</sub> in the high‐dose ibuprofen group 0.48%, (95% CI 0.19 to 0.78). This translated to an absolute 2.5% smaller decline in FEV<sub>1</sub> over five years. Adjusting for the use of inhaled tobramycin or dornase alfa (typically used in people who are more ill) strengthened the effect. However, adjusting for individuals who discontinued the ibuprofen did not appear to affect the results, even though these tended to be those with more advanced disease. There was an increase in the risk of hospitalization for gastrointestinal bleed with high‐dose ibuprofen. However, the risk of gastrointestinal ulcer or renal failure was not increased. More recently, the Epidemiological Study of Cystic Fibrosis, with follow‐up data from the US Cystic Fibrosis Foundation Patient Registry, found the use of high‐dose ibuprofen slowed the decline in lung function and improved long‐term survival (<a href="./references#CD001505-bbs2-0028" title="KonstanMW , VanDevanterDR , SawickiGS , PastaDJ , ForemanAJ , NeimanEA , et al. Association of high‐dose ibuprofen use, lung function decline and long‐term survival in children with cystic fibrosis. Annals of the American Thoracic Society2018;15(4):485‐93. ">Konstan 2018</a>). </p> <p>Conventional therapy for CF is an evolving practice that requires constant evaluation of new treatments and therapies. To date, the study of NSAIDs to slow down the progression of lung deterioration has relied solely on the comparison of a placebo group on a background of other accepted therapies. To our knowledge, there have been no comparisons between different anti‐inflammatory therapies or other medications, such as azithromycin, which may have beneficial anti‐inflammatory effects (<a href="./references#CD001505-bbs2-0032" title="SouthernKW , BarkerPM , SolisA . Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD002203.pub2] ">Southern 2004</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001505-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 1 Annual rate of change in % predicted FEV1." data-id="CD001505-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 1 Annual rate of change in % predicted FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 2 Annual rate of change in % predicted FEV1 (split by age)." data-id="CD001505-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 2 Annual rate of change in % predicted FEV<sub>1</sub> (split by age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 3 Annual rate of change in % predicted FVC." data-id="CD001505-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 3 Annual rate of change in % predicted FVC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 4 Annual rate of change in % predicted FVC (split by age)." data-id="CD001505-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 4 Annual rate of change in % predicted FVC (split by age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 5 Annual rate of change in % predicted FEF25%‐75%." data-id="CD001505-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 5 Annual rate of change in % predicted FEF<sub>25%‐75%</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 6 Annual rate of change in % predicted FEF25%‐75% (split by age)." data-id="CD001505-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 6 Annual rate of change in % predicted FEF<sub>25%‐75%</sub> (split by age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 7 Proportion with at least one respiratory hospitalisation." data-id="CD001505-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 7 Proportion with at least one respiratory hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 8 Proportion with at least one hospital admission." data-id="CD001505-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 8 Proportion with at least one hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 9 Number of deaths." data-id="CD001505-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 9 Number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 10 Annual rate of change in % ideal body weight." data-id="CD001505-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 10 Annual rate of change in % ideal body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 11 Annual rate of change in % ideal body weight (split by age)." data-id="CD001505-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 11 Annual rate of change in % ideal body weight (split by age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 12 Chest X‐ray score." data-id="CD001505-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 12 Chest X‐ray score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 13 Chest X‐ray score (split by age)." data-id="CD001505-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 13 Chest X‐ray score (split by age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 14 Increase in abdominal pain." data-id="CD001505-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 14 Increase in abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 15 Decrease in abdominal pain." data-id="CD001505-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 15 Decrease in abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 16 Proportion with at least one gastrointestinal hospitalisation." data-id="CD001505-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 16 Proportion with at least one gastrointestinal hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 17 Stool frequency." data-id="CD001505-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 17 Stool frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 18 Occult blood." data-id="CD001505-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 18 Occult blood. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 19 Increase in epistaxis." data-id="CD001505-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 19 Increase in epistaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 20 Decrease in epistaxis." data-id="CD001505-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 20 Decrease in epistaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 21 Increase in conjunctivitis." data-id="CD001505-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 21 Increase in conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 22 Decrease in conjunctivitis." data-id="CD001505-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 22 Decrease in conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 23 Increase in nausea." data-id="CD001505-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 23 Increase in nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001505-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/urn:x-wiley:14651858:media:CD001505:CD001505-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_t/tCD001505-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 24 Increase in diarrhoea." data-id="CD001505-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 24 Increase in diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/media/CDSR/CD001505/image_n/nCD001505-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001505-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population</b>: adults and children with cystic fibrosis </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: NSAIDs </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>All participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.15%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the NSAIDs group was <b>1.32% higher</b> (0.21 higher to 2.42 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>Subgroup: under 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.32%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted for under 13 year olds in the NSAIDs group was <b>1.41% higher</b> (0.03 higher to 2.80 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FEV<sub>1</sub> </b> </p> <p>Subgroup: over 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted in the placebo group was ‐3.18%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FEV<sub>1</sub> % predicted for over 13 year olds in the NSAIDs group was <b>0.75% higher</b> (1.02 lower to 2.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>All participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.31%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the NSAIDs group was <b>1.27% higher</b> (0.26 higher to 2.28 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>Subgroup: Under 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.65%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted for under 13 year olds in the NSAIDs group was <b>1.32% higher</b> (0.04 higher to 2.60 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual rate of change in % predicted FVC</b> </p> <p>Subgroup: Over 13 years of age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted in the placebo group was ‐2.03%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean annual rate of change in FVC % predicted for over 13 year olds in the NSAIDs group was 0.78<b>% higher</b> (0.71 lower to 2.27 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion with at least 1 hospital admission</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>440 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>268 per 1000</p> <p>(163 to 444)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.61 (0.37 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286 (4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>FVC:</b> forced vital capacity; <b>NSAIDs:</b> non‐steroidal anti‐inflammatory drugs; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to high risk of bias due to selective reporting.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: non‐steroidal anti‐inflammatory drugs compared with placebo for lung disease in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/full#CD001505-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001505-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral nonsteroidal anti‐inflammatory drug versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Annual rate of change in % predicted FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.21, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Annual rate of change in % predicted FEV<sub>1</sub> (split by age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.07, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Under 13 years at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.03, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 13 years or over at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [‐1.02, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Annual rate of change in % predicted FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.26, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Annual rate of change in % predicted FVC (split by age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.12, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Under 13 years at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.04, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 13 years and over at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [‐0.71, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Annual rate of change in % predicted FEF<sub>25%‐75%</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.15, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Annual rate of change in % predicted FEF<sub>25%‐75%</sub> (split by age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.10, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Under 13 years at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [‐0.09, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 13 years or older at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [‐1.22, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion with at least one respiratory hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proportion with at least one hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.37, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Annual rate of change in % ideal body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Annual rate of change in % ideal body weight (split by age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.08, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Under 13 years at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.33, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 13 years or older at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐0.61, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Chest X‐ray score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐0.08, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Chest X‐ray score (split by age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [‐0.04, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Under 13 years at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐0.24, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 13 years or older at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐0.30, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Increase in abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.20, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Decrease in abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Proportion with at least one gastrointestinal hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Stool frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Occult blood <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Increase in epistaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Decrease in epistaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Increase in conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.22, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Decrease in conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Increase in nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Increase in diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral nonsteroidal anti‐inflammatory drug versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001505.pub5/references#CD001505-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001505.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001505-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001505-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001505-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD001505-note-0013">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD001505-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001505-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD001505-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001505-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001505\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001505\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001505\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001505\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001505\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001505.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001505.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001505.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001505.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001505.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719868494"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001505.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719868498"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001505.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df3444c2c937f',t:'MTc0MDcxOTg2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 